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Abstract 
The cornea acts as a transparent shield protecting the eye from germs, dust and pathogens as 
well as regulating the ocular environment by controlling the diffusion of external substances 
like oxygen or drugs via the tear film into the intraocular tissues. The design and development 
of an intraocular-drug delivery device highly depend upon the understanding of the interactions 
between the biological system of the eye and the drug-ophthalmic material complex. In vivo 
models have been used in clinical studies as the necessary and most valid testing platforms for 
regulatory authorities, but animal experiments have always been widely criticized for ethical 
and economical reasons. Furthermore, when studying interactions in the eye environment, 
using animal models has other disadvantages such as difference in blinking patterns, tear 
composition, and organ size when compared to the human eye. Therefore, in vitro cell culture 
models using human cells have been considered as a powerful pre-screening tool for drug 
testing to study interactions with the ocular tissue. In vitro models also provide an experimental 
environment, in which each parameter can be controlled. With a lower complexity level and 
less variability, in vitro models allow gaining a better understanding of the parameters involved 
in the drug delivery system.  
Using eye drops for ocular drug delivery to the anterior section of the eye is a significant 
challenge due the rapid washout in tears and the corneal barrier to drug diffusion. Therefore 
mimicking this environment in vitro can help in designing more robust drug delivery system 
for the front of the eye. 
This research focuses on the application and characterization of an in vitro human corneal 
model which mimics in part the in vivo environment to assess corneal interaction with the 
drug/biomaterial complexes. In this project, an in vitro model using human corneal epithelial 
cells is used to characterize the drug release profile and transport from commercially available 
contact lenses. Three model drugs for treatment of glaucoma, eye inflammation and infection 
respectively were tested in combination with two commercial contact lenses with different 
surface chemistry and their release profiles were measured. The effects of biological 
transporters on the controlled release systems were investigated. The role of organic anion 
transporter protein OATP 2A1 (prostaglandin transporter) in transcellular transport of 
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Latanoprost was characterized and the presence of its gene in the HPV16 E6/E7 immortalized 
corneal epithelial cell line was verified by real-time polymerase chain reaction. To assess the 
role of OATP 2A1, transporters were inhibited by Diclofenac sodium and the release kinetics 
of Latanoprost from Pure Vision® (balafilcon A) and Acuvue Oasys® (senofilcon A) contact 
lenses in three in vitro conditions with live corneal cells monolayer, fixed epithelial cells and 
transporter inhibited epithelial cells were studied.   
The presence of corneal epithelial cells in vitro had a significant effect on release kinetics of 
Latanoprost resulting in a zero-order release profile. Complete inhibition of the OATP 2A1 
transporter reduced the release rate of Latanoprost by 30% and 52% from balafilcon A and 
senofilcon A respectively.  Comparison between live, fixed and transport inhibited models 
indicated that Latanoprost transport occurred mainly through the active transcellular pathway 
but was not mediated only by OATP 2A1. Other transporters might be involved in the transport 
and further research is required to identify these.  
The effect of initial loading concentration of Latanoprost on release rate and amount of drug 
eluted from contact lenses was also investigated. Reduction in initial loading concentration of 
the drug increased the released percentage of the drug from 6.9% to 14.1% for balafilcon A 
and from 11.4% to 57.3% for senofilcon A. Both silicone hydrogel contact lenses, regardless 
of initial loading concentrations, released Latanoprost at above therapeutic daily dose up to 96 
hours with zero-order constant rate.  
The release kinetics of two hydrophilic ophthalmic drugs, Ciprofloxacin HCl and Timolol 
Maleate also from the soft contact lenses were evaluated in the corneal in vitro model over 48 
hours. The effect of corneal epithelial barrier on the release kinetics of these hydrophilic drugs 
was evaluated. The release kinetics of hydrophilic Ciprofloxacin HCl and Timolol maleate 
followed a first-order rate. The presence of corneal epithelial cells in vitro had no significant 
effect on the release rate of hydrophilic drugs. However, presence of cells (live or fixed) acted 
as a diffusion barrier by decreasing the amount of Ciprofloxacin released from silicone 
hydrogel contact lenses compared to no-cell in vitro model.  No significant difference in 
released amount of Timolol was observed between live, fixed and no cell in vitro models  
Our results further confirmed the effect of chemical interaction between drug molecules and 
contact lens polymer on a controlled release system and the importance of selecting the 
 v 
appropriate in vitro model. Testing conditions and presence of biological barriers provided by 
cells can have a significant impact on release profile and provided a more realistic test platform 
for studying the release kinetics for the ocular environment. All in all, this thesis confirms the 
importance of proper selection of in vitro test models for the assessment of ocular drug delivery 
system and suggests that commercially available silicone hydrogel ocular materials may be 
used effectively for the release of hydrophobic therapeutics.  
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Chapter 1 
Introduction 
   Topical drug delivery to the eye remains a significant challenge for scientists and engineers 
due to the unique anatomy of the eye and its physiology, that lower the bioavailability of topical 
ophthalmics administration to less than 5% (Sjöquist et al., 1998). The main route for drug delivery 
to the anterior eye is the cornea (Gaudana et al. 2009, 2010).  The cornea is a transparent functional 
barrier protecting the eye from infections, the entrance of germs, dust or pathogens as well as 
regulating the internal environment of the eye by controlling the diffusion of external substances 
or drugs into the intraocular tissues. Development of new treatments for corneal injuries and the 
design of effective intraocular drug delivery systems highly depend upon the understanding of how 
the visual organ works and the biological roles of each tissue in the eye (Castro-Muñozledo, 2008). 
As part of the development and design of such systems, studying cytotoxicity and biocompatibility 
of biomaterials/drugs used for the treatment of eye diseases/injuries or controlled released systems 
is paramount, and relies on comprehension of the biological interactions between biomaterials, the 
drugs and the biological hosts (Williams, 2014, 2008).  In other words, each biomaterial-drug-host 
complex has its own characteristics and must be studied as a system (Williams, 2014).  
To develop drug delivery systems and characterize biocompatibility requires experimental models, 
such as in vitro, in vivo or ex vivo models, where toxicity, efficacy and other parameters can be 
tested.  Animal models, still used as the most valid test beds for regulatory authorities in clinical 
studies, have always been criticized due to ethical issues since a high number of animals has to be 
sacrificed to collect sufficient tissue samples. While in vivo experiments cannot be removed 
completely to obtain approval for clinical studies, there is a strong call to reduce the number of 
required in vivo experiments to a minimum (Hornof et al., 2005). Furthermore using animal models 
to study ocular materials and drug delivery systems has some other disadvantages such as  inter-
sample variations, different blinking patterns and tear composition than human and different organ 
size/surface compared to the human eye (Urtti and Salminen, 1993). The development of in vitro 
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models using human cell lines has thus been considered as a powerful pre-screening tool for 
studying the tissue barrier function and tissue regulations as well as for testing pharmaceuticals. 
Furthermore, in vitro models provide controlled experimental conditions, in which each parameter 
can be regulated  to obtain more reproducible results in comparison to the more complex ex vivo 
studies with dissected animal tissues or in vivo tests (Hornof et al. 2005; Reichl et al. 2011). 
Therefore in order to use in vitro cell culture instead of animal models and extract meaningful 
information from in vitro cell interactions with drugs and biomaterials comparable to in vivo and 
clinical results, it is crucial to design an in vitro model which addresses the key natural 
characteristics of the extracellular matrix (ECM) as well as the biophysical, biochemical and 
biomechanical properties of the native cell niche in the tissue (Bacakova et al., 2011; Castro-
Muñozledo, 2008).  
This research thesis aimed to characterize a corneal in vitro model and assess the role of live 
corneal epithelial cells in application of this model for testing controlled delivery of ophthalmics. 
This thesis starts with an introduction to the anatomy of the eye and the cornea, and ocular drug 
delivery concepts in Chapter 2.  In this chapter, ocular barriers and corneal transporters are briefly 
reviewed; glaucoma, Latanoprost and silicone hydrogel contact lenses are introduced and ocular 
in vitro models discussed. In Chapter 3, a corneal epithelial in vitro model is described and 
characterized for ocular transporters. The results on the role of transporters in Latanoprost 
transcorneal permeation are reported. Chapter 4 presents the release kinetic studies of Latanoprost 
from silicone hydrogel contact lenses in different corneal in vitro models. Chapter 5 reports the 
examination of corneal in vitro model for assessment of hydrophilic drugs release from silicone 
hydrogel contact lenses. Finally, Chapter 6 and Chapter 7 present the conclusions and 
recommendations for future work, respectively.  
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Chapter 2   
Background 
2.1 Human Eye 
Eyes are complicated organs through which we sense and comprehend the outside world. 
As a vital organ, the eye is protected by the surrounding bones in the skull called the bony orbit. 
The eyeball (globe) is also wrapped in layers of fat and supporting tissues for protection and 
stability (Lens et al. 2008).  Figure 2-1 schematically illustrates the overall topographic anatomy 
of the human eye. As shown in the figure, the globe is not completely round and is made of two 
merged unequal spheres joined at the junction of the cornea and the conjunctiva. The sagittal 
diameter of an adult globe is about 24 mm and its volume is about 6.5 ml. The weight of the globe 
is about 28 grams.  The most outer skeleton of the eye is formed by the fibrous envelope of the 
cornea and the sclera. The cornea is shaped like an ellipsoid and covers about 20% of the eye total 
surface. The remainder 80% of the globe surface is covered by the sclera (Rodrigues, 1996).  
 
Figure 2-1 Schematic presentation of human eye (adapted with permission from CC: By Holly Fischer, © Regents 
of the University of Michigan http://creativecommons.org/licenses/by/3.0/) 
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The globe can be divided into two asymmetric portions namely the anterior segment and 
the posterior segment.  The posterior segment is larger (two third of the eye globe) than the anterior 
part and includes the structures posterior to the lens such as the choroid, macula, retina, posterior 
sclera and optic nerve. (Figure 2-1).  The posterior segment is filled by a gel like fluid called the 
vitreous humor.  The anterior segment (also called the front of the eye) consists of the pupil, the 
crystalline lens, cornea, iris, conjunctiva and ciliary body. The anterior segment is divided by the 
iris into the anterior and the posterior chambers which are filled by the aqueous humor (Rodrigues, 
1996, Lens et al. 2008). The light is first refracted through the cornea and then via the pupil passes 
through the lens and the vitreous humor until it reaches the visual receptor cells of the retina called 
rods and cones, which convert the light to nerve impulses. These impulses are transmitted to the 
brain via optic nerves for further visual processing (Lens et al., 2008).  The eye is comprised of 
several components and layers. However, only the structures relevant to this thesis will be 
reviewed in the next sections.  
2.1.1 Cornea 
The cornea is the strongest refractive component of the entire visual system and the main 
chemical and mechanical barrier of the anterior eye which protects the anterior segment and the 
intraocular tissues from external substances and contaminations (Lens et al. 2008). The cornea is 
transparent, avascular and consists of three cellular layers and two acellular supporting membranes 
with a thickness of ~ 500µm (Huhtala et al., 2008).  The outmost apical part consists of 5-6 layers 
of stratified non-keratinized squamous corneal epithelium cells supported by the Bowman’s 
membrane basally and covered by the tear film laterally (Lens et al., 2008). The top superficial 
epithelial cells are flattened and are connected to each other with desmosomes and tight junctions 
and form a strong diffusional barrier against exogenous materials. Beneath the superficial cells are 
2-3 layers of wing cells followed by a monolayer of columnar basal cells attached to the Bowman’s 
membrane. Proliferation occurs at the basal cells and cells differentiate and stratify as they 
propagate and move upward to wing cells and then to flattened superficial cells. Corneal epithelial 
cells eventually shed from the top layer at the surface and will be replaced by the cell layers beneath 
(Lens et al., 2008).  The main role of the Bowman’s membrane is to act as a supporting ECM for 
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epithelial cells; its surface topography is porous with micro to nano sized pores, bumps and fibers 
which are stochastically dispersed (Garland et al., 2014). Under the Bowman’s membrane is the 
stroma which represents ~90 percent of the corneal thickness. It contains arranged collagen fibers, 
proteoglycans and fibroblastic keratocytes (stromal cells) and lies on the Descemet’s membrane, 
which separates the stroma from a monolayer of polygonal endothelial cells. Endothelial cells 
separate the cornea from the aqueous humor and are responsible for keeping the stroma slightly 
dehydrated and clear. However, the transparency of the cornea also relies on other factors such as 
fast proliferation of basal epithelial cells, homeostasis and metabolic activity of keratocytes and 
the endothelium as well. Figure 2-2 presents a cross-section of a human cornea (Barar et al., 2008; 
Hornof et al., 2005; Huhtala et al., 2008; Reichl et al., 2011). The different layers of the corneal 
epithelium are clearly distinguishable in Figure 2-2.B (Reichl et al., 2011)  
  
Figure 2-2 A cross-section of the human cornea (A). The cornea consists of the epithelium, the stroma and 
endothelium cell layers. The corneal epithelium has five to six cell layers (B). Magnified cross-section of corneal 
epithelial cells illustrating the flattened superficial cell layers, wing cells and columnar monolayer attached to 
Bowman’s membrane. Proliferation occurs at the basal layer and the cell differentiation happens to wing cells as 
they grow. At the apical surface, cells become flattened and form a tight barrier (adapted with permission from 
Reichl et al., 2011) 
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The corneal surface is covered by a thin film of tear, renewing with a turnover rate of 0.5-2.2µl/min 
in humans (Mishima et al., 1966). The tear film is responsible for lubrication of the cornea and 
since it is located at the air-eye interface, it also provides oxygen and nutrients to it. It partially 
refracts light and also contributes to light refraction by maintaining the corneal surface clear and 
distortion free (Rodrigues, 1996). The tear film is also a diffusional barrier against drugs and 
exogenous materials via lacrimal drainage (Hornof et al. 2005; Lens et al. 2008).  The tear film 
structure is illustrated in the Figure 2-3. The tear film is believed to consist of four immiscible 
layers (over the last decades, there has been several debates about the layering of the tear film 
(Butovich et al. 2008; Green-Church et al. 2011; Prydal and Campbell, 1992; Sullivan, 1994). The 
inner mucin layer is 0.2-0.5µm in thickness and helps to attach to the hydrophobic ocular surface. 
The intermediate aqueous layer is 6-7µm in thickness and contains inorganic salts, glucose, urea, 
proteins, glycoproteins and surface active polymers. This central layer is responsible for 
lubrication of the ocular surface while blinking.   The outer lipid bilayer with a thickness of ~0.1µm 
is composed of an outer nonpolar layer in contact with the air interface guarding against water 
evaporation and an inner polar layer, responsible of stabilizing the outer layer. It mainly contains 
low polar lipids and waxy esters (Green-Church et al., 2011).  
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Figure 2-3. A proposed model for the structure of the precorneal tear film (taken with permission from Butovich 
et al., 2008)  
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2.2 Ocular Drug Delivery 
In the design and development of ophthalmics, it is critical to consider parameters such as 
bioavailability (a measurement of the rate and amount of a drug that reaches the target site in an 
unchanged chemical form via blood circulation system (Griffin and Grady, 2002); drug delivery 
system, tolerability and stability of the final drug formulations; the commercial drug system must 
be an ideal compromise of these parameters (Ali and Lehmussaari, 2006). To deliver the drug to 
the target site, a drug carrier strategy is needed which leads to design of a drug delivery system. A 
drug delivery system can also be designed as a controlled release system to minimize the pulsatile 
variation of drug concentration at the target tissue and keep it at the effective therapeutic levels 
and below toxic levels in the period of treatment (Figure 2-4) (Novack, 2009). This system must 
be also stable in the physiological environment and be tolerated by the site of action (target tissue) 
(Griffin and Grady, 2002).  
Due to the unique anatomy and physiology of the eye and the presence of various barriers, 
ocular drug delivery in a sustained and controlled manner has been a major challenge for scientists 
and pharmacologists in the design of ophthalmic drug delivery systems ( a Urtti, 2006).  In general, 
drug delivery to the eye is classified into anterior and posterior segments. The majority of the 
anterior eye diseases are usually treated by conventional drug delivery dosage forms such as 
topically instilled ophthalmic eye drops (solutions), ointments, gels and suspensions (Gaudana et 
al., 2009). Medications applied to the outer surface of the eye for treatment of infections are also 
classified into anterior segment drug delivery systems. Injectable drugs, oral doses and ocular 
inserts are other types of conventional dosage which are used when the active ingredient is 
topically impermeable or the target site is not accessible by topical administration (Lang, 1995). 
However, these methods are not efficient and each has drawbacks such as blurring vision, low 
bioavailability, low drug penetration to the anterior chamber and poor patient compliance. For 
topically administered ophthalmics, most of the applied dose is rapidly washed out by tear fluid 
turnover, blinking and through the lacrimal drainage; less than 5% of the drug is actually absorbed 
to the ocular surface due to lacrimal drainage and tear fluid turnover (Sjöquist et al. 1998). 
Therefore a frequent dose application by the patient is required, which may increase pulsatile 
variations in the drug concentration. Increasing the dose or the frequency of administration may 
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also cause ocular toxicity (Figure 2-4). Low stability and presence of preservatives and penetration 
enhancers in the formulation of these ophthalmics are also other disadvantages pertaining to the 
conventional dosages. In the design of ocular drug delivery systems, these problems can be solved 
with various approaches by extending residence time of the drug, providing controlled release, 
designing prodrugs, using carriers and transporters/receptors and more local delivery by implants 
(Ciolino et al., 2009; White et al., 2011a).  
 
 
Figure 2-4. Drug concentration in the tear film after topical administrations. Graph A represent the conventional 
frequent application with a high dose which may reach to the toxicity threshold. Graph B shows a low dose 
application which is not efficient. Graph C represent the ideal dosing at a constant rate which keeps the drug 
concentration at therapeutic level. (taken with permission from White and Byrne 2010)  
 
2.2.1 Ocular barriers  
There are several possible routes of ocular drug delivery into the ocular tissues and various 
cellular membranes and barriers control the transport of fluids and solutes into the eye as well as 
effectively hamper the penetration of exogenous molecules, pathogens and unfortunately ocular 
therapeutics. Hence, in the design of an ocular drug delivery system, the functionality and 
  10 
characteristics of these biological barriers must be fully understood and addressed  (Barar et al., 
2008; Hornof et al., 2005; Urtti, 2006). Figure 2-5 illustrates the biological barriers of the eye. 
Topically administered drugs are adsorbed through the anterior segment including the cornea, 
sclera and conjunctiva while oral dosage and systematically administered drugs penetrate into 
intraocular tissues via the blood-retina barrier (BRB) and blood-aqueous barrier (BAB). 
Intravitreal injection is another route (invasive method) to reach to the vitreous humor. BRB 
surrounds the posterior segment of the eye and includes two layers of inner retinal capillary 
endothelial cells and outer retinal pigment epithelium. The presence of tight junctions in the retinal 
epithelium and endothelium makes the BRB a strict barrier against traverse of nutrients, proteins 
and small hydrophilic compounds (del Amo and Urtti, 2008; Gaudana et al., 2009; Hughes et al., 
2005).  The BAB is located at the anterior part of the eye (Figure 2-5) and consists of two cellular 
layers of the endothelium of the iris/ciliary blood vessels and the non-pigmented ciliary epithelium. 
This barrier controls the traverse of solutes, large molecules and proteins into the aqueous and 
vitreous humors and is responsible for keeping the intraocular fluids clear. The small and lipophilic 
drugs in the vitreous humor are eliminated through the BAB while larger hydrophilic drugs are 
washed away by aqueous humor turnover (Barar et al., 2009, 2008).  
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Figure 2-5. Schematic illustration of the biological barriers in the human eye. The first barrier against installed 
drugs is the tear film (0). The cornea is the main route of transport for topically administered (1). The conjunctival 
and scleral route has a lesser hydrophilic drugs (2). Iris blood vessels are the routes for drug with small molecules 
to penetrate from the systemic circulation into the anterior chamber (3). The drugs are washed out of the anterior 
chamber either by aqueous humor outflow via trabecular meshwork (4) or by diffusing across the iris surface via 
by venous blood flow (5). Systemically administered drugs can diffuse into or be removed from the vitreous 
through the blood–retinal barrier (6, 8). Intravitreal injection is another route (invasive method) to reach to the 
vitreous humor (7). Drugs can diffuse into the anterior chamber from the vitreous humor (9) (taken with 
permission from Barar et al., 2008). 
 
Most of the anterior segment diseases are usually treated by topical administration. Topical 
penetration routes for ocular drug delivery are classified into corneal and non-corneal (conjunctiva 
and sclera) routes. The corneal route is the major pathway for topical ocular drug delivery while 
the non-corneal route is considered to be inefficient for most of ophthalmics since drugs 
penetrating through the conjunctiva and sclera are eliminated into the systematic circulation via 
local capillary beds. Although the cornea is the main route of drug penetration, the presence of the 
corneal epithelium makes it the rate limiting barrier against drugs, and the permeability of 
compounds highly depends on the size and physiochemical characteristics of the drug molecules. 
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Large and hydrophilic drugs are mostly absorbed through the conjunctiva and sclera while small 
hydrophobic drugs penetrate through the cornea into the aqueous humor (Barar et al., 2009, 2008; 
Hornof et al., 2005;  Urtti, 2006).  Figure 2-6 illustrates the cellular organization of the cornea with 
its various transport barriers. As mentioned earlier, the corneal epithelium consists of superficial 
cell layers, wing cells and basal cells which are connected together with desmosomes and tight 
junctions making a strong barrier with just 10-20 nm cavities between cell layers. Tight junctions 
are part of the epithelial cell membranes at the apical side where two cells fuse together and make 
a tight barrier so that exogenous materials cannot pass between two interacting cells; the superficial 
cell monolayer then regulates the passage of molecules via transcellular active transport (see 
below). Desmosomes are molecular complexes of cell adhesion and linking proteins which are 
responsible for attachment of cell surface adhesion proteins to intracellular keratin cytoskeletal 
filaments (Hall, 1990; Sunkara and Kompella, 2003).  
There are two parallel penetration pathways through the cornea:  
- paracellular transport, which is driven by passive diffusion between the cells across the 
continuous corneal epithelium 
 - transcellular transport, which is mediated actively by cellular receptors and carriers through 
the lipid bilayer of the cell membrane.  
Paracellular transport is limited by the size and charge of permeating molecule whereas 
transcellular movement depends on the interaction between transporters/receptors and the drug 
molecules (Dey et al., 2003). The mechanism of topical drug absorption to the cornea is a 
combination of both transports although, based on physiochemical characteristics of the drug 
molecules, one of them is the dominant transport pathway (Huang et al., 1983; Schoenwald and 
Huang, 1983).   Epithelial cells selectively control the transport of hydrophilic compounds that can 
easily pass through the stroma and endothelial cells. On the other hand, hydrophobic drugs have a 
higher transcellular permeability through the corneal epithelial cells but have a lower permeability 
through the stroma (Mannermaa et al., 2006). 
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Figure 2-6 Cellular organization of the cornea showing its various transport barriers. Topmost layers of epithelial 
cells with tight junctions make a strong barrier monolayer. The basal endothelial monolayer is more permeable.  
(taken with permission from Barar et al., 2008) 
2.2.2 Corneal Transporters 
Membrane transporters/receptors play a critical role in transport processes of drugs, absorption, 
distribution and elimination of nutrients, ions and solutes in and out of the ocular cells. As 
mentioned in the previous section, corneal epithelial cells impose a tight barrier against xenobiotics 
and drugs, protecting the anterior part of the eye while the blood–retina barrier controls the traverse 
of systematically administered drugs to the posterior segment. By revealing the functional role of 
transporters/receptors, it has become evident that they are critically important in pharmacokinetics 
of ophthalmic drugs (Nies et al. 2011). Studying the transport processes existing in ocular barriers 
and selecting the proper drug delivery strategies utilizing these transporters and receptors can 
significantly improve the drug bioavailability to the target ocular tissue (Barnstable, 2008).   
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In ocular tissues, the two principal families of transporters are the efflux transporters (export 
pumps) and the influx transporters (uptake pumps). Influx transporters mediate the uptake of 
substances from the extracellular space into cells, and efflux transporters facilitate the secreting of 
substances out of cells.  Figure 2-7 presents the currently known transporters of the corneal 
epithelium. The influx transporters in the cornea include amino acid transporters (LAT1, ATB0+, 
and ASCT1), oligopeptide transporters (PepT1, PepT2, PHT1 and PHT2), monocarboxylate 
transporters (MCT), nucleoside transporters (CNT3) and organic anion transporting polypeptides 
(OATP2). Most of these influx transporters belong to the solute carrier (SLC) superfamily. The 
efflux transporters consist of P-glycoprotein (P-gp), multidrug resistant protein (MRP) and breast 
cancer related protein (BCRP). All of these efflux transporters belong to the ATP binding cassette 
(ABC) superfamily (Barnstable, 2008; Dey et al., 2003; Mannermaa et al., 2006).  
 
Figure 2-7. Schematic representation of the currently known transporters/receptors in the corneal epithelium 
(taken by permission from Barar et al., 2008) 
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Organic anion transporting polypeptides (OATPs) are a group of membrane carriers with 
a wide spectrum of amphiphilic substrates. Genes that encode for the OATPs are classified as the 
SLCO family. The OATP family consists of 11 members including the prostaglandin transporter 
OATP2A1 which is the shortest protein in its family with only 643 amino acids and is widely 
expressed in ocular tissues and particularly in human cornea (Kraft et al., 2010; Science and Haven, 
1997). Prostaglandins (PGs) play an important therapeutic role in treatment of human ocular 
hypertension (glaucoma) and lowering the intraocular pressure (IOP) (Kashiwagi et al., 2002; 
Salvador, 1972). At physiological pH (7.0-7.4), PGs are charged anions and can poorly cross the 
lipid bilayer of cell membranes. The transport of prostaglandin is mediated by OATP2A1 
transporters in the ocular tissues (Science and Haven, 1997; Kraft et al. 2010).  
2.3 Latanoprost and Glaucoma 
Glaucoma is a disease affecting more than 60 million people worldwide and is known as 
the second leading cause of irreversible blindness, happening often in elderly people. The number 
of people suffering from glaucoma is estimated to reach 80 million worldwide by 2020 (Quigley 
and Broman, 2006). In the United States alone, the number of people with glaucoma is 
approximately 2.5 million leading to annual US healthcare costs of about $2.5 billion (Mills et al., 
2006).  
Glaucoma is a group of ocular disorders mainly caused by ocular hypertension leading to 
progressive optic nerve damage, loss of vision and visual field defects. Glaucoma is most often 
due to increased IOP (Casson et al., 2012; Green, 1998). IOP is created by a dynamic balance 
between inflow and outflow of aqueous humor in anterior and posterior chambers. The aqueous 
humor is a watery fluid which is produced in ciliary body at a rate of ~2.5 µl/min (inflow), occupies 
the anterior chamber (AC) and posterior chamber (PC) and drains through trabecular meshwork to 
the canal of Schlemm (outflow).  Normal IOP is in a range of 10-21 mmHg but when the balance 
between inflow and outflow is disrupted, it will lead to an elevated IOP which causes ocular 
hypertension and eventually optic nerve damage (glaucoma) (Lens et al., 2008).  
Glaucoma can be categorized roughly into two main types, Open-Angle Glaucoma (OAG) and 
Angle-Closure Glaucoma (ACG). However, there are five basic subtype of glaucoma which are 
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clinically classified and are presented in the Table 2-1 (Casson et al., 2012). Primary open angle 
glaucoma is the most common form of glaucoma accounting for more than 90% of US cases of 
glaucoma patients (Mills et al., 2006).  OAG has no symptoms other than elevated IOP until the 
patient loses vision. ACG has acute symptoms such as headache, redness, blurred vision and pain 
in the eye or even nausea and vomiting (Adatia and Damji, 2005). Although invasive surgical 
techniques are sometimes used to treat the acute ACG, IOP reduction with medication is the most 
common treatment strategy for all types of glaucoma, including normal tension glaucoma (NTG) 
(Casson et al., 2012).   
 
 Table 2-1. Basic classification of the glaucomas (Casson et al., 2012) 
Subtypes of Glaucoma Conditions  
Primary Open-Angle Glaucoma (POAG) IOP is elevated but no pathological cause is identified.  
Secondary Open-Angle Glaucoma (SOAG) IOP is high and the cause of elevated IOP is clinically 
identified.  
Primary Angle-Closure Glaucoma (PACG) A subtype of closed angle glaucoma with the elevated IOP but 
no identifiable cause.  
Secondary Angle-Closure Glaucoma 
(SACG) 
Elevated IOP with Identifiable pathological cause  
Normal Tension Glaucoma (NTG) A subtype of POAG where IOP is normal and no pathological 
cause is identified.  
 
Various categories of ocular hypertensive drugs containing active ingredients such as β-blockers, 
carbonic anhydrase inhibitors, prostaglandin analogues and α-adrenergic agonist or combinations 
of them are used in the form of eye drops for lowering the IOP in early diagnosis of glaucoma 
(Hariharan et al., 2009).  Timolol Maleate, a β-blocker, was the first anti-glaucoma medication 
introduced in 1978. Later in 80s and early 90s, several other selective and non-selective β-blockers 
were introduced into the market.  Apraclonidine and Brimonidine were α-adrenergic agonists 
which were introduced in 1988 and 1996 respectively. The effect of prostaglandin analogues on 
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lowering the IOP was reported first in 1985 and the first most potent prostaglandin prodrug to 
receive FDA approval in 1996 was Latanoprost in 1996 (Shah et al., 2011). Prostaglandin F2α 
analogues have shown an effective reduction of the IOP (Hariharan et al., 2009; Russo et al., 2008; 
Sjöquist and Stjernschantz, 2002a; Sjöquist et al., 1998). Latanoprost is designed as a lipophilic 
prodrug in which the carboxylic acid moiety in the α-chain has been esterified. Latanoprost is 
hydrolyzed to the free-acid form to increase the bioavailability of the active drug into the eye (Fig 
2-8) by esterases in the cornea. The Latanoprost free-acid is the pharmacologically active form of 
the drug and increases the outflow of the aqueous humor at the trabecular meshwork (Toris et al., 
2008).  
 
 
22-8. Chemical structure of Latanoprost and its respective free acid form (taken with permission from Sjöquist 
and Stjernschantz, 2002a) 
 
The marketed anti-glaucoma drug (Xalantan) contains 50 µg/ml of Latanoprost. The effective 
adult recommended daily dose is one drop per affected eye which contains 1.5µg of Latanoprost 
(Electronic Medicines Compendium, eMC www.medicines.org.uk).  Clinical studies have shown 
that the maximum concentration of Latanoprost active form (Latanoprost free acid) detected in 
aqueous humor after 1-2 hour of administration is about 150-300 ng which is only 2% of the 
applied dose (Sjöquist and Stjernschantz, 2002). However it has been shown that this amount 
reduces the IOP effectively in open angle glaucoma patients for 24 hours (Diestelhorst et al., 1997; 
Dubiner et al., 2004).    
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The poor bioavailability of Latanoprost and the lack of compliance by patients can lead to further 
vision impairment. Therefore designing a drug delivery system for Latanoprost which can increase 
the drug ocular surface retention time and delivers the drug on an extended period of time, can 
increase drug bioavailability while decreasing the frequency of administration and reliance on 
patient compliance and can improve the prognosis of glaucoma patients.   
2.4 Silicone Hydrogel Contact Lenses as drug delivery systems  
To overcome the low bioavailability of the topical drug instillation, regardless of corneal 
barrier and drug properties affecting absorption, one strategy is to increase the residence time of 
the drug on the ocular surface. This objective has been achieved by various approaches such as 
increasing the drug solution viscosity, using drug loaded gels, mucoadhesive formulations, ocular 
inserts, nanoparticles, emulsions and therapeutic contact lenses. (Chaiyasan et al., 2013; Gaudana 
et al., 2010; Lang, 1995). Among these, using contact lenses as a polymeric reservoir for 
ophthalmic drugs has been viewed as the most convenient approach due to the high degree of 
comfort, biocompatibility, and the potential for significantly increasing ocular drug retention time 
and bioavailability.  
Contact lenses were developed more than half a century ago for vision correction and since have 
also been considered as an alternative for ocular drug delivery. First generation contact lenses were 
made of poly(methylmetacrylate) (PMMA) which had many disadvantages including low oxygen 
permeability and low water content (Guillon and Guillon, 1989; Robertson et al., 2007). The next 
generations of contact lenses were developed based on poly-2-hydroxyethyl methacrylate 
(pHEMA) (conventional contact lenses) with some also incorporating siloxane groups (silicone 
hydrogel contact lenses). Silicone hydrogel contact lenses have excellent oxygen permeability, a 
key characteristic for extended wear of contact lens. However, their hydrophobic surface chemistry 
can be the cause of discomfort and tear film destabilization. The hydrophilicity (wettability) of 
silicone hydrogels are significantly improved by surface treatment and incorporation of wetting 
agents (Stapleton et al., 2006). US food and Drug Administration (FDA) has categorized soft 
hydrogel contact lenses in four groups based on their water and ionic contents (Table 2-2). Silicone 
hydrogel contact lenses mostly belong to group I and III, which have a water content of less than 
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50%. Table 2-3 summarizes the characteristics of common commercially available silicone 
hydrogel contact lenses (Stapleton et al. 2006).   
Contact lenses have been considered for ocular drug delivery for more than 50 years (Sedlácek, 
1965). Several methods have been used to load and impregnate the contact lens with drugs in order 
to get the optimum controlled release rate. These methods include drug soaking, molecular 
imprinting and carrier/surfactant mediated release using nanoparticles and liposomes. for complete 
reviews please refer to (Bengani et al., 2013; Guzman-Aranguez et al., 2013; Hsu et al., 2014; 
White et al., 2011). Drug-soaked contact lenses are the most common and easiest technique to 
obtain a release system for ophthalmics. Commercially available extended wear contact lenses, 
particularly silicone hydrogels, can be promising platforms to be used for extended release of drug 
to the anterior eye for treatment of diseases like glaucoma (Bengani et al., 2013; Kim et al., 2008).  
  
 
Table 2-2. FDA classification of soft contact lenses (FDA Soft Contact Lens Grouping System 2014, 
www.fda.gov)  
FDA-group  Water Content (%) Ionic content (%) 
Group I  below 50%  below 0.2% 
Group II  above 50%  below 0.2% 
Group III  below 50%  above 0.2% 
Group IV  above 50%  above 0.2% 
Group V* (A) below 50% below 0.2% 
Group V* (B) below 50% above 0.2% 
Group V* (C) above 50% below 0.2% 
*Group I-IV are conventional hydrogels and group V are silicone hydrogels  
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Table 2-3. Characteristics of silicone hydrogel contact lenses (adapted with permission from Stapleton et al., 2006) 
Commercial name Acuvue Oasys Pure Vision Focus Night&Day O2Optix Acuvue Advance 
(US adopted name) senofilcon A balafilcon A Lotrafilcon A Lotrafilcon B Galyfilcon A 
Manufacturer Johnson &Johnson Bausch & Lomb CIBA Vision CIBA Vision Johnson &Johnson 
Water content (%) 38 36 24  33 47 
Principal Monomer mPDMS 
+ DMA + HEMA +  
siloxane macromer +  
TEGDMA + PVP 
 
NVP + TPVC  
+ NVA + PBVC 
DMA, TRIS,  
siloxane macromer 
DMA, TRIS,  
siloxane macromer 
mPDMS, DMA, HEMA 
siloxane macromer 
TEGDMA, PVP 
Surface modification Plasma oxidation 
producing glassy 
islands 
None 
Internal wetting 
agent  (PVP) 
25 nm plasma 
coating with high 
refractive index 
25 nm plasma 
coating with high 
refractive index 
None 
Internal wetting agent 
(PVP) 
FDA group  (I) 
Low water 
Non-ionic 
 (III) 
Low water 
Ionic 
(I) 
Low water 
Non-ionic 
(I) 
Low water 
Non-ionic 
(I) 
Low water 
Non-ionic 
NVP N-vinyl pyrrolidone; TPVC tris-(trimethylsiloxysilyl) propylvinyl carbamate; NCVE N-carboxyvinyl ester; PBVC poly[dimethylsiloxyl] di[silylbutanol] 
bis[vinyl carbamate]; DMA N,N-dimethylacrylamide;  
HEMA 2-hydroxyethylmethacrylate; MA methacrylic acid; PVP polyvinylpyrrolidone;  
mPDMS monofunctional polydimethylsiloxane; TEGDMA tetraethyleneglycol dimethacrylate; EGDMA ethyleneglycol dimethacrylate. 
 21 
 
2.5 Ocular In vitro Models 
The Draize eye irritation test using live rabbits and dogs was developed in the 1940’s and 
has been the only valid toxicity test accepted by regulatory authorities since 1964.  The Draize eye 
test has been widely criticized due to ethical and cost issues.  Ex vivo test models using dissected 
animal eyes and corneas, are being used as alternatives but suffer from similar criticism as they 
still lead to animal sacrifices (Castro-Muñozledo, 2008; Draize et al., 1944; Huhtala et al., 2008; 
York and Steiling, 1997). Cell immortalization and cell culture techniques have enabled the 
development of in vitro ocular models.  Extensive research has led to promising test platforms for 
assessing the drug permeability, ocular bioavailability and toxicity as well as studying the 
biological interaction of drug releasing materials (Castro-Muñozledo, 2008). The cornea is the 
topmost outer surface of anterior eye with the maximum penetration resistance and rate-limiting 
barrier for permeation to the anterior chamber, therefore corneal models consists mostly of 
stratified corneal epithelial cells (Castro-Muñozledo, 2008; Postnikoff et al., 2014; Robertson et 
al., 2011).  Other commercial and experimental multilayer corneal constructs containing stroma 
and endothelium, have also been successfully developed (Castro-Muñozledo, 2008; Huhtala et al., 
2008; Reichl 2004; Reichl et al., 2011).  
2.5.1 Primary Cell Culture    
Corneal cultures using isolated primary cells from humans and animals have been 
extensively described in the literature (Castro-Muñozledo 2008; Reichl et al. 2011). Techniques 
for the culture of primary cells have been developed since 1940s and several protocols have been 
established using rabbit cells because of their rapid proliferation rate and their potential to compare 
to in vivo test results since most of the in vivo tests are performed in rabbits. However, the main 
challenges in cultivating primary corneal epithelial cells in vitro are developing appropriate growth 
conditions for long-term survival and stable expression of differentiated phenotypes and 
establishing culture conditions close to their natural environment to enable the cells to proliferate 
and differentiate into a stratified multilayer (Hornof et al., 2005; Castro-Muñozledo, 2008; Reichl 
et al., 2011). Using primary human corneal primary cells in vitro for assessment of drug 
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permeability and toxicity is not routine due to the high variability in phenotype, the instability in 
gene expression of different donor samples, as well as their short life span. Many attempts have 
been made to resolve the shortcomings of using primary cells  by modifying culture condition and 
culture media to extend the life span, increase the number of sub-cultures and the stability of 
differentiated phenotypes (Castro-Muñozledo, 2008; Hornof et al., 2005). However, immortalized 
human cell lines appear to be more suitable for routine and screening tests (Hornof et al., 2005).  
2.5.2 Immortalized Cell Culture 
Following the development of genetic engineering techniques, a variety of immortalized 
corneal cell lines has been established from human, rabbit, hamster and rat corneas. 
Immortalization of mammalian cells provides an alternative to address the high demand for use of 
animal models in biomedical and pharmaceutical research. Following isolation of cells from the 
tissues, these techniques establish cell lines which have the ability to grow and differentiate under 
defined culture conditions for high number of passages without any major instability in phenotype 
gene expression (Hornof et al. 2005; Castro-Muñozledo 2008; Huhtala et al. 2008).  Most of 
immortalization of corneal epithelial cells is induced with oncogenes such as Simian Virus SV40, 
SV40-LT antigen and human papilloma virus HPV16 and HPV18. However, immortalization with 
viral oncogenes has some drawbacks such as the resistance to final differentiation and phenotype 
instability. Researchers have thus explored another immortalization approach by increasing the 
telomerase activity of cells. The mechanism of the shortening of the telomere during each cell 
division works as a mitotic clock and is responsible for controlling the cell life-span. By 
inactivation of p16, p53 and hTERT gene expression (which are responsible for telomere 
shortening), corneal epithelial cells are immortalized. Instead of genetic manipulation to 
immortalize epithelial cells, extended serial subcultures can also lead to isolation of spontaneous 
immortalized cell lines. However, these procedures are difficult and depend highly on the cell type, 
animal species and the tissue from which cells are isolated. Using immortalized corneal cell lines 
in in vitro models has major advantages like extended life span and fast growth with improved 
conditions that provide a high-throughput tool for screening and assessment of drugs (Castro-
Muñozledo 2008).  
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2.5.3 Corneal Epithelial In vitro Models 
On the ocular surface, the cornea is the main route of topical drug absorption with the 
corneal epithelium being the outer most surface. Therefore, current research in the field of drug 
delivery of ophthalmics is highly focused on corneal interactions with drugs and biomaterial at the 
tissue, cellular and molecular levels (Järvinen et al., 1995; Reichl et al., 2011; Sandeman et al., 
2003). 
Numerous corneal models have been developed by using different cell culturing techniques. These 
vary from culturing a simple monolayer of epithelium on a permeable membrane (Reichl et al., 
2011) to differentiated stratified corneal epithelium models (Postnikoff et al., 2014). Models gain 
complexity from being a co-culture of epithelium-stroma or epithelium-3T3 fibroblast to the most 
complex engineered 3D corneal equivalents containing epithelium, stroma and endothelium layers 
(Castro-Muñozledo, 2008; Germain et al., 2000; Reichl, 2004; Reichl et al., 2011). Figure 2-9 
illustrates the variety of different corneal models based on their specificity versus their complexity. 
These models, constructed with different cell culturing methods have various applications from 
simple in vitro toxicity test and drug permeability to construction of whole corneal equivalent for 
tissue implantation. Corneal epithelial monolayer models are mostly used for toxicity and eye 
irritation tests (Huhtala et al., 2008; Reichl et al., 2011; Toropainen et al., 2001).  By developing 
more complex corneal models consisting of endothelial, stromal and epithelial layers constructed 
(Figure 2-10) on cell culture inserts, researchers hope to find better correlations between in vivo 
and in vitro results (Hornof et al. 2005; Huhtala et al. 2008).  Various extracellular factors are 
involved in development of a three dimensional corneal model. As the corneal epithelium is 
exposed to the air interface in vivo, an air-liquid interface in the in vitro model is critical for 
differentiation of the corneal epithelium. This interface leads to the development of apical flat cells 
with desmosomes and tight junctions which carry out the barrier function. 
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Figure 2-9 Corneal models constructed with cell culture techniques (taken with permission from Huhtala et al. 
2008) 
 
 
 
Figure 2-10 Step by step construction corneal equivalent. A-D Structural layers of the cornea are seeded layer by 
layer on the cell culture inserts and are differentiated to form a stratified epithelium with an air-cell interface 
(taken with permission from Huhtala et al., 2008). 
 
The in vitro corneal models used for the assessment of ocular barrier function are made of stratified 
corneal epithelium multilayers or stratified epithelium multilayers co-cultured with stroma or 3T3 
fibroblasts (Ban et al., 2003). Expression of differentiated keratocyte-specific biomarkers is a key 
indicator of a successful development of a stratified 3D corneal epithelium model. Therefore 
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modulation of cell proliferation and differentiation using modification of supplemented culture 
media, co-culture techniques and grafting culture inserts with ECM proteins are established 
methods by researchers for the development of corneal models mimicking the corneal barrier 
function. Another element which should not be neglected is the expression of transporters at the 
gene and molecular levels when these models are used for drug permeation and screening studies 
(Castro-Muñozledo, 2008; Dey et al., 2003; Forbes and Ehrhardt, 2005; Hornof et al., 2005; 
Mandery et al., 2010). Postnikoff et al. for the first time developed a curved stratified corneal 
epithelium in vitro model to assess the ocular biocompatibility of contact lens-multipurpose 
solution. This 3D corneal epithelium model was reconstructed successfully with the real human 
eye curvature using immortalized human corneal epithelial cells that proliferated and stratified on 
a collagen coated cellulosic membrane. This 3D model would fit well the curvature and the area 
of contact lenses, and is a suitable platform for ocular biocompatibility assessment of contact 
lenses, multipurpose solutions and any other topical ophthalmics (Postnikoff et al. 2014).  
Only a few whole cornea models have been developed so far that can mimic the in vivo 
environment. Minami et al. have isolated bovine endothelial, stromal and epithelial cells and 
cultured them in a 3D collagen matrix. In this model, the cells express the cornea specific keratin 
biomarkers and the epithelium consists of 5–6 layers of stratified differentiated cells. This was the 
first reconstructed corneal equivalent from primary cells (Hornof et al. 2005). Griffith et al., 
successfully constructed a functional human cornea from immortalized cell lines consisting of 
three cellular compartments of epithelium, stroma and endothelium as well as two acellular 
Bowman’s and Descemet’s membranes. The equivalent cornea mimicked major physiological and 
morphological functions as well as the transparency of the real human cornea. This in vitro human 
corneal construct showed similar level of expression of genes and key biochemical markers of 
human cornea (Li et al., 2005, Griffith, 1999).    
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Chapter 3 
Characterization of the Human Corneal In vitro Model 
3.1 Introduction 
The main objective of this study was to characterize an in vitro corneal epithelial cell model 
previously used in Dr. Gorbet’s lab and further investigate the transport of Latanoprost (a 
glaucoma drug) released from a contact lens.  As previous results by Mohammadi et al., (2014) 
showed that live cells in the in vitro models had a significant effect on the extended release of 
Latanoprost from a contact lens (Mohammadi et al., 2014), it is hypothesized that active 
transcellular transport mediated by certain drug transporters in the corneal epithelium is involved 
in transport of Latanoprost. It is also hypothesized that, for Latanoprost, the transcellular active 
transport is more important than the passive diffusion in paracellular transport. To test these 
hypotheses, the presence of organic anion transporting polypeptide 2A1 (OATP2A1), which is 
responsible for the transport of prostaglandins in the human cornea, was investigated at the gene 
expression level. To further study the potential role of the OATP2A1 transporters in transcorneal 
diffusion of Latanoprost, the effect of Diclofenac, a cyclooxygenase inhibitor, on the function of 
OATP2A1 transporters was studied. 
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3.2 Materials and Methods 
3.2.1 Preparation of Drug Solution 
Latanoprost was bought from Cayman Chemical (Ann Arbor, MI, USA) as 5mg aliquot in 
a solution of methyl acetate.  To obtain a solution of 50µg/ml, the 5mg of Latanoprost aliquot was 
dissolved in 100ml of phosphate buffered saline (PBS) (Lonza, Walkersville, MD) The 
concentration of the stock drug solution was then measured by enzyme immuno assay (EIA) (see 
below) and determined to be 161.2±36.5µg/ml.  The solution was further diluted and concentration 
confirmed at 19.3±3.4µg/ml. All Latanoprost solutions were stored at – 20 °C.     
3.2.2 Preparation of Contact Lenses 
Two commercially available silicone hydrogel contact lenses, balafilcon A and senofilcon A 
were used in this study. The chemical properties of these lenses are presented in the Table 3-1. 
Lenses were first incubated for 24 hours in PBS to remove any remnants of their packaging 
solution. The lenses were then incubated in 1.5ml of the drug solution (total amount of Latanoprost 
available to contact lens was 29 µg) for 24 hours. 
Table 3-1 Properties of the Contact Lens Hydrogel Materials (Mohammadi et al., 2014) 
Commercial name Acuvue Oasys Pure Vision 
(US adopted name) senofilcon A balafilcon A 
Manufacturer Johnson &Johnson Bausch & Lomb 
Water content 38 36 
Principal Monomer mPDMS 
+ DMA + HEMA +  
siloxane macromer +  
TEGDMA + PVP 
 
NVP + TPVC  
+ NVA + PBVC 
Surface modification Plasma oxidation 
producing glassy islands 
None 
Internal wetting agent – (PVP) 
FDA group  (I) 
Low water 
Non-ionic 
 (III) 
Low water 
Ionic 
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3.2.3 Cell Culture 
The HPV16-E6/E7 immortalized human corneal epithelial cells (HCEC) generously gifted 
by Dr. Griffith, University of Ottawa Eye Institute, Ottawa, ON, Canada (Griffith et al., 1999) 
were cultured in a 25cm2 treated tissue culture flask containing 10ml of keratinocyte serum free 
medium (KSFM) supplemented with keratinocyte growth supplement (KGS), and 
penicillin/streptomycin (Pen/Strep) (ScienCell, Carlsbad, California, USA) at 37◦C and 5% carbon 
dioxide (CO2). Every other day, the medium was renewed and cells were monitored for any 
morphological changes. After cells reached 90% confluency, adherent cells were removed 
following a 15-minute incubation in 3ml TryplExpress (Life Technologies Burlington, Ontario, 
Canada) dissociation solution at 37◦C and 5% CO2. Dissociated cells were centrifuged at 1200 rpm 
for 7 minutes and were washed with 10ml medium supplemented with 10% fetal bovine serum 
(FBS) (Life Technologies Burlington, Ontario, Canada), then were ready to use. 
3.2.4 Flat Monolayer HCEC Model.  
To develop a transcorneal flat monolayer in vitro model, polyethylene terephthalate (PET) 
membrane inserts (Millicell PET membrane with a 1.0m pore size, also referred to as culture 
inserts, Millipore, MA, USA) were set in a 12 well plate. The PET inserts were incubated with 90 
µl of 0.05 mg/ml Collagen type I from rat tail (ScienCell Carlsbad, California, USA) for 30 
minutes. Following collagen coating, the inserts were washed with 500 µl of PBS (Lonza, 
Walkersville, MD) and were then seeded with 105 cells per well. The corneal epithelium models 
were fed with KSFM on each of the basal and apical sides of the cell layers for 6 days in order for 
the monolayer to form tight junctions. The medium was exchanged every other day. 
3.2.5 Fixing cells 
To investigate the role of metabolically active cells versus a physical barrier of cell 
monolayer to drug permeation, a set of experiments was designed to compare Latanoprost release 
from a contact lens through a fixed and a live monolayer corneal model. In the fixed monolayer, 
cells are dead and thus neither metabolic activity nor active transport occurs. The only transport 
would be a passive paracellular diffusion. Cells were fixed for 24 hours with a 2% 
paraformaldehyde solution in PBS.   
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3.2.6 Transport Inhibition 
The nonsteroidal anti-inflammatory drugs (NSAIDs) are inhibitors of both isoforms of 
cyclooxygenase, COX-1 and COX-2, which are the rate limiting enzymes for the synthesis of 
prostaglandins (Cryer and Feldman, 1998). Diclofenac, a NSAID, can inhibit completely the 
OATP 2A1 transporter responsible for the transport of prostaglandins in cells (Mandery et al., 
2010).  Diclofenac sodium salt (Sigma-Aldrich Catalogue No. 93484) was dissolved in KSFM at 
the concentration of 100 µM (Mandery et al., 2010). To inhibit the potential prostaglandin 
transporters in the corneal epithelial cells, at day 5, some of the corneal epithelial monolayers were 
incubated in 1.5 ml of the Diclofenac solution for 24 hours before the release experiments.      
3.2.7 MTT viability Assay 
The MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5 diphenyl tetrazolium bromide) assay measures 
mitochondrial activity and is based on the conversion of MTT into formazan crystals by living 
cells.  For most cells, the total mitochondrial activity is related to the number of viable cells, thus 
this assay is broadly used to assess viability and  cytotoxic effects of drugs on cell lines  (Cree, 
2011; Mosmann, 1983).  To perform the MTT assay, the tetrazolium salt was dissolved in pre-
warmed KSFM at 0.5 mg/ml and then sterilized through a 0.2µm pore sized filter. 0.5ml and 1ml 
of MTT solution was applied to the basal and apical surfaces of the monolayer respectively.  After 
three hours of incubation at 37°C and 5% CO2, the inserts were covered with the dark purple 
formazan crystals (Figure 3-1). The formazan crystals were dissolved in 1.5ml of isopropanol on 
the apical and basal side of the cell culture inserts. The inserts with isopropanol were left on a 
shaker for 2 hours in order to ensure complete dissolution of the formazan. The apical and basal 
formazan solutions were mixed and an aliquot of formazan solution was read on a UV-Vis plate 
reader at wavelengths of 595nm and 620nm. 
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Figure 3-1. Human corneal epithelial cells were grown on PET membrane insert and were stained with MTT on 
the 6th day of growth (left). Formazan (purple) crystals inside cells (right) indicate viable cells.  
 
3.2.8 In Vitro Drug Release Experiment 
Three in vitro models were used to assess the effect of active transport on the release kinetics of 
Latanoprost from commercially available contact lenses. The in vitro models used diffusion 
through a monolayer of human corneal epithelial cells (HCECs), through a transport inhibited 
HCECs monolayer and a fixed monolayer of HCECs. Aliquots of 50µl were taken from the bottom 
of the in vitro models and replaced by fresh culture medium. Samples were taken at 1, 4, 8, 12, 24, 
48, 72 and 96 hours. Collected samples were analyzed by an enzyme immuno-assay (EIA) for 
Latanoprost (Cayman Chemical, Ann Arbor, MI, USA). Following the EIA kit instructions, each 
collected sample was analyzed in duplicate and at two different dilutions. Each set of experiments 
was repeated 3 times independently on different days. Drug concentrations were calculated based 
on the previously published study from Gorbet’s research laboratory (Mohammadi et al., 2014). 
Briefly, samples were taken from the bottom of the wells and replaced by fresh medium at each 
time point. In order to consider the dilution rate and to calculate the absolute amount of drug 
released at each point, mass balance principles were applied. To estimate the actual concentration 
at each time point, the equation below was used: 
Ca,i=Ci+k ∑ Cj
i-1
j=1
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𝐶𝑎,𝑖is the actual concentration at the time point 𝑡𝑖. 𝐶𝑖 is the measured concentration at the time 
point 𝑡𝑖, k is the fraction of the total medium volume at the bottom of the wells which was 
aliquoted. ∑ 𝐶𝑗
𝑖−1
𝑗=1  is the summation of concentrations measured before time point 𝑡𝑖.  The effect 
of dilution on the diffusion rate of the drug was assumed to be insignificant due to the small 
difference in the total volume of medium after sampling (Mohammadi et al., 2014).  
3.2.9 RNA Isolation and Real Time PCR 
Total RNA from corneal epithelial cells grown to confluence in a 25 cm2 flask was 
extracted with an RNA isolation kit (Illustra RNAspin Mini; GE Healthcare, Little Chalfont, 
Buckinghamshire, UK) based on the company’s protocol. RNA samples were stored at -80 °C until 
analysis.  
The reverse transcription of extracted RNA (2 µl each) was performed using Superscript III kit 
(Invitrogen, Carlsbad, CA) based on the company’s protocol. The cDNA was amplified in a 
sequence detection system (ABI 7900HT; Applied Biosystems) at 45 cycles of 50°C for 2 minutes, 
followed by denaturation at 95°C for 15 seconds, and then annealing at 60°C for 1 minute. 
Predesigned primers and TaqMan probes for SLCO2A1 (OATP2A1) and the housekeeping genes 
β-actin (ACTB) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used 
(Hs00194554_m1, Hs00200670_m1, Hs00357333_g1, Hs00266705_g1; Applied Biosystems) 
(Kraft et al., 2010; Mandery et al., 2010).   
3.2.10 Gel Electrophoresis 
Agarose gels (1.5%) were obtained by dissolving 0.75 g agarose in 50 ml of Tris Acetate 
EDTA (TAE) buffer heated to its boiling point. After complete dissolution of agarose, the solution 
was cooled down for 5 minutes and 0.2 µl GelRed dye (Biotium, Inc. Hayward, CA USA) was 
added. The solution was cast into the mold plate and the gel film was formed within 30 minutes. 
Amplified PCR cDNA samples were mixed with DNA dye (bromophenol blue) at a ratio of 1:5. 
The agarose gel was placed into a Bio-Rad mini sub-cell and filled with Tris Acetate EDTA buffer 
to cover the entire gel surface. 18 µl of cDNA samples with dye were loaded in each well and 
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electrophoresis was run at 85V and 300 mA until the samples had migrated to within ¾ of the 
positive electrode end of the gel. The gel was removed and photographed under UV lamp.  
3.2.11 Data Analysis 
All results were expressed as the mean ± standard deviation of three independent 
experiments. Statistical analysis was performed by two-way analysis of variance (ANOVA) using 
Minitab Express™ Software. A p value of less than 0.05 was required for statistical significance.   
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3.3 Results  
3.3.1 The effect of active transport on release of Latanoprost 
The release profiles of Latanoprost from balafilcon A through live, transporter-inhibited 
and fixed monolayer in vitro models are presented in Figure 3-2.  The maximum amount of 
Latanoprost released from balafilcon A after 96 hours was 1.8±0.2µg in the live HCEC monolayer 
model. The least amount of Latanoprost (0.3±0.0µg) was released in the monolayer model where 
cells had been fixed. As can be seen on Figure 3-2, the release profiles of Latanoprost in all three 
models were linear with approximately constant rates (R2>0.99). Table 3-2 reports the Latanoprost 
release rate from balafilcon A. The average release rates for balafilcon A in live, inhibited and 
fixed models were 19.1±1.8, 13.3±3.1 and 2.9±0.3 ng/hour respectively. Inhibiting transporters in 
the HCEC monolayer led to approximately 36±1% reduction in the total amount of Latanoprost 
released from balafilcon A after 24 hours (1.2±0.3 µg), a 30% reduction in the rate of release 
(Table 3-2). The release rate and the amount of released drugs were significantly affected by 
inhibition of transporters in immortalized HCECs compared to live HCEC monolayer model (p 
<0.0001). Figure 3-4 presents the rate of inhibition calculated based on the amount of released 
drug through live, transport inhibited and fixed cell models over 96 hours of experiment. As seen 
in the figure, after 24 hours, the percentage of inhibition remained constant up to 48 hours and 
started to unexpectedly be less effective after that. Fixing the cells also led to 83±1.5% decrease 
in the amount of released Latanoprost (~85% decrease in the release rate from balafilcon A).   
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Figure 3-2. Latanoprost release from balafilcon A contact lenses through live, transporter-inhibited and fixed 
HCEC monolayer models. Cells were fixed in 2% paraformaldehyde. Lenses were soaked for 24 hours in drug 
solution (29 µg Latanoprost) and then overlaid on the monolayer for 96 hours, n = 3, Mean ±SD.  
* Significantly different compared to transport inhibited model (p< 0.0352) 
 
 
Table 3-2. Average Latanoprost release rate from balafilcon A and senofilcon A silicone hydrogel in 96 hours 
 
Contact lens 
Average Release Rate (ng/hour)§ 
In vitro Model 
 Live Transport Inhibited Fixed 
balafilcon A 19.1±1.8* 13.3±3.1 2.9±0.3* 
senofilcon A§ 34.6±6.7* 16.6±2.7 2.4±0.6* 
* Significantly different compared to transport inhibited model (p<0.0001) 
§ Significantly different compared to balafilcon A (p=0.0095) 
 
 
Figure 3-3 presents the release profiles of Latanoprost from senofilcon A through the live, transport 
inhibited and the fixed corneal in vitro models. The total amount of Latanoprost released from 
senofilcon A in the live monolayer model was 3.2±0.6 µg after 96 hours; this significant increase 
in release is almost twice the amount released from balafilcon A in the same in vitro model 
(p=0.0322). The total amounts of drug released from senofilcon A after 96 hours were 1.6±0.3 µg 
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and 0.2±0.1 µg in the transport inhibited and the fixed cell models respectively. Similar to 
balafilcon A, the release profiles of Latanoprost in all three models were linear throughout the 96 
hours of the experiments with a constant release rate (R2>0.99) (Table 3-2). The average rate of 
release for senofilcon A through live, inhibited and fixed cell models were 34.6±6.7, 16.6±2.7 and 
2.4±0.6 ng/hour respectively. Inhibiting transporters in the HCEC monolayer by 100µM of 
Diclofenac sodium after 12 hours decreased the total amount of Latanoprost released from 
senofilcon A by approximately 58±3% and remained constant up to the end of the experiments 
(see Figure 3-4).   This translated to a 52% reduction in the average rate of release as shown in 
Table 3-2. Fixing the cells caused a 91±3.4% reduction in total amount of released drug from 
senofilcon A (a reduction of 93% in release rate).  
 
 
Figure 3-3. Latanoprost release from senofilcon A contact lenses through live, transporter inhibited and fixed 
HCEC monolayer models. Cells were fixed in 2% paraformaldehyde. Lenses were soaked for 24 hours in drug 
solution (29 µg Latanoprost) and then overlaid on the monolayer for 96 hours. Release experiments were 
conducted in three separate dates n = 3, Mean + SD. 
* Significantly different compared to transport inhibited model at all time points after 12 hours (p<0.0005)  
 
Overall, inhibition of transporters in immortalized HCECs significantly affected the release rate 
and the amount of released drugs compared to live HCEC monolayer model (p<0.0001). It is also 
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important to highlight that in all 3 models, Latanoprost release from balafilcon A was significantly 
lower than senofilcon A (p= 0.0322). Analysis of variances (ANOVA) indicated that contact lens 
materials and in vitro models had significant effects on the release kinetics of Latanoprost 
(p<0.0001); however the interaction effect of contact lens type and in vitro model was not 
significant (p =0.062).  
 
 
Figure 3-4.  Transport inhibition of organic anion transporter protein OATP 2A1 by 100 µM Diclofenac 
throughout 96 hours of Latanoprost release from balafilcon A and senofilcon A silicone hydrogel contact lenses. 
Inhibition percentage is calculated based on the difference between the average released amount of drug from 
lenses through live and inhibited monolayer in vitro models, n = 3, Mean ±SD  
3.3.2 Real Time PCR 
The real-time polymerase chain reaction amplification graphs for the organic anion 
transporter protein genes SLCO 2A1 responsible for the expression of the OATP 2A1 protein 
(prostaglandin transporter) are presented in Figure 3-5.  Comparison of the SLCO 2A1 to the 
housekeeping genes indicated that SLCO 2A1 cDNA was amplified, confirming the presence of 
this gene in the immortalized human corneal epithelial cell line. The gel electrophoresis results 
from the amplified cDNA samples (Figure 3-6) further highlight the presence of the OATP 2A1 
gene in the human corneal epithelial cell line.      
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Figure 3-5 Real-Time PCR Amplification graphs. SLCO2A1 (light green), Beta Actin (Blue), GAPDH (Orange). 
2µl of cDNA sample were run at 2 dilutions (1X and 10X). 2µl of RNA samples were used as negative control  
 
 
Figure 3-6. Gel Electrophoresis of amplified cDNA samples. Sample 2 is 10X dilution of sample 1.  2µl of RNA 
samples were used as negative control  
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3.4 Discussion 
In our three cell models, the release profiles of Latanoprost from both contact lenses were linear, 
indicative of a controlled release with constant rate. These results are in agreement with results 
presented previously by Mohammadi et al. (2014). In this study, the amount of drug released in 48 
hours from silicone hydrogels loaded with ~185µg Latanoprost increased from 0.3-0.5 µg in a no-
cell model to 2.5-4.5 µg in a model using a monolayer or a multilayer of corneal epithelial cells.   
Lower amounts of Latanoprost were released from contact lenses when cells were fixed or 
inhibited.  These results thus confirm that the presence of live cells in the in vitro model 
significantly affects the rate of release and amount of eluted Latanoprost from balafilcon A and 
senofilcon A. Considering the hydrophobic nature of Latanoprost and its high affinity for the lens 
polymer, it can be postulated that an active transport mechanism mediated by cell transporters is 
involved in the transport of Latanoprost in the corneal in vitro model.  OATP2A1 is a well-known 
transporter responsible for transport of prostaglandins (Kraft et al., 2010; Mandery et al., 2010) 
and its presence in the HPV16 E6/E7 immortalized human corneal epithelial cells was confirmed 
by RT-PCR. Furthermore, the significant decrease in the rate and amount of released Latanoprost 
following inhibition of this transporter with 100µM of Diclofenac sodium confirmed the role of 
active transcellular transport in the experimental model. Based on previous work by (Mandery et 
al., 2010), Diclofenac sodium at 100µM is expected to completely inhibit OATP2A1 transporters 
in HCEC.  However, only a 40 to 50% reduction in transport was achieved suggesting that other 
transporters may be responsible for active transport of Latanoprost through the cornea.  The fact 
that over 90% of Latanoprost transport was inhibited by paraformaldehyde fixation indicates that 
cellular active transport governs transcorneal permeation of the hydrophobic Latanoprost.  
The zero order release rates observed in this study also suggest that loading of Latanoprost prodrug 
in balafilcon A and senofilcon A can potentially provide a simple platform for a sustained 
controlled release system which may be able to deliver Latanoprost to the eye at a constant rate 
within the therapeutic range and during an extended period of time. Further investigation is needed 
to determine effective dosing for extended drug delivery purposes, which will be discussed in the 
next chapter.  
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Chapter 4 
Application of the Human Corneal In vitro Model to assess 
Latanoprost Controlled Released System 
4.1 Introduction 
This part of the project was defined with the perspective of designing a controlled release 
device using commercially available extended-wear contact lenses loaded with lower amount of 
Latanoprost (low dose therapeutic extended-wear contact lens). Mohammadi et al. 2014 previously 
showed a linear release of Latanoprost from three silicone hydrogel contact lenses (balafilcon A, 
senofilcon A and galyfilcon A) in the presence of live cells. While 95% of the Latanoprost in 
solution (131 µg/ml) was uptaken in lenses, less than 4% of the uptaken drug was released. This 
is due to the high affinity of the hydrophobic drug to the contact lens.  Despite overall low release 
from the lenses, this amount was still much higher than the required therapeutic level (150-300ng) 
of Latanoprost. In this study, it was hypothesized that by loading lower concentration of 
Latanoprost on contact lenses, the therapeutic amount of the drug could still be released and in 
turn increase the efficacy and economy of the controlled release system. To test this hypothesis, 
the uptake and release kinetics of silicone hydrogel contact lenses loaded with lower amount of 
Latanoprost over an extended period of time was assessed.   
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4.2 Materials and Methods 
4.2.1 Preparation of Drug Solution 
The drug solutions with concentrations of 19.3, 4.8 and 2.9 µg/ml were obtained by dilution 
of Latanoprost stock solution (as explained previously in section 3.2.1).     
4.2.2 Preparation of Contact Lenses 
Two commercially available silicone hydrogel contact lenses, balafilcon A and senofilcon 
A were used in this study. The chemical properties of these lenses were presented in the Table 3-
1. Lenses were first incubated for 24 hours in PBS to remove any remnants of their packaging 
solution. The lenses were then incubated in 1.5ml of the drug solution (total amounts of 
Latanoprost available to contact lenses were 29.0, 7.2 and 4.3 µg) for 24 hours. 
4.2.3 Latanoprost Uptake and Release 
After incubation with the drug solutions, the lenses were set on the in vitro corneal model. 
The volume of liquid in the insert was 0.5ml and 1.0ml in the bottom well. The release was studied 
for up to 96 hours. Aliquots of 50µl were taken from the bottom of the in vitro models and replaced 
by fresh culture medium. Samples were taken at 4, 12, 24, 48, 72 and 96 hours. Collected samples 
were analyzed by an EIA kit for Latanoprost (Cayman Chemical, Ann Arbor, MI, USA). 
Following the EIA kit instructions, each collected sample was analyzed in duplicate and at two 
different dilutions. To determine the uptake amount by the contact lenses, samples were also 
collected from the soaking drug solution as well as the remaining drug solutions after soaking the 
lenses. Each set of experiment were repeated for three times independently. Drug concentrations 
were calculated based on the equation explained previously in Chapter 3.  
4.2.4 Data Analysis 
Results presented here are the mean±standard deviation of three independent experiments. 
Statistical analysis of the data was performed by two-way analysis of variance (ANOVA) using 
Minitab Express™ Software. A p level of less than 0.05 was required for statistical significance.    
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4.3 Results  
4.3.1 Latanoprost Uptake and Release 
The Latanoprost uptake and release data for both balafilcon A and senofilcon A contact 
lenses are presented in Table 4.1. The theoretical expected concentration of the drug solution and 
actual initial concentrations of drug loading solution measured by EIA are also presented in this 
table. As shown in the table, more than 95% of Latanoprost available to the lenses was uptaken in 
24 hours regardless of initial concentration. The maximum drug loaded was 28.9 µg (99.5±0.1% 
uptake) for balafilcon A with initial loading amount of 29.0±5.1 µg Latanoprost.  The minimum 
drug loaded was 4.2 µg with initial loading amount of 4.3±0.3µg Latanoprost. As expected, there 
was a significant effect of initial loading concentrations on the uptake amount of Latanoprost to 
contact lenses (p=0.0001) but there was no effect of contact lens materials (p=0.6316).  
The maximum amount of drug released after 96 hours was 4.1±0.3 µg which represented 
57.2±3.5% of the uptaken drug by senofilcon A with the initial loading amount of 7.2±0.6 µg. The 
minimum amount released after 96 hours was 0.5±0.1 µg from balafilcon A loaded with 4.3±0.3 
µg.  After 96 hours, senofilcon A released significantly more Latanoprost than balafilcon A 
regardless of initial amount of loading (p=0.0007).  The amounts of drug released from both 
silicone hydrogel contact lenses with initial loading conditions of 29.0 and 7.2 µg were 
significantly higher than the amount released from these lenses loaded with 4.3 µg (p=0.007); 
regardless of contact lens type. There was no significant difference in the release amount between 
initial loading conditions of 29.0 and 7.2 µg (p=0.7920).    
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Table 4-1 Latanoprost uptake into balafilcon A and senofilcon A contact lenses and total amount of drug released after 96 hours through the live HCEC monolayer in vitro 
model. Lenses were soaked for 24 hours in different concentrations of Latanoprost solutions and then drug uptake into the lens were measured. Uptake experiments were 
conducted in three separate dates (n = 3, Mean ± SD) except for drug solutions containing 7.2 µg Latanoprost (n=2, Mean ± SD)   
Theoretical concentration1    
10 6 3 
(µg Latanoprost/ml) 
Actual loading concentration2    
19.3 ± 3.4 4.8 ± 0.4 2.9 ± 0.2 
(µg Latanoprost/ml) 
Loading dose (µg) 29.0 ± 5.1 7.2 ±0.6 4.3 ± 0.3 
 
 
Uptake Release3 Uptake Release3 Uptake Release3 
 
 
(%) (µg) (%) (µg) (%) (µg) (%) (µg) (%) (µg) (%) (µg) 
 
balafilcon A 
 
99.5±0.1 28.9±0.0 6.1±0.6 1.8±0.2 95.7±0.9 6.9±0.1 14.2±6.5 1.0±0.5 97.8±0.9 4.2±0.0 12.2±3.1 0.5±0.1*  
 
senofilcon A 
 
98.6±0.6 28.6±0.2 11.3±2.2§ 3.2±0.6§ 96.0±1.0 6.9±0.1 57.3±3.5§ 4.1±0.3§  97.4±0.2 4.2±0.0 32.2±11.9§ 1.4±0.5§*  
1 Expected (nominal) concentration based on the manufacturer’s label 
2 Concentration of the solution measured by EIA 
3 The release percentage was calculated based on the ratio of the released amount over the uploaded amount of drug per contact lens. 
§ Significantly different compared to balafilcon A (p < 0.0001)  
* Significantly different compared to 7.2 and 29.0 µg loading amount (p < 0.003)  
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4.3.2 Latanoprost Release Kinetics 
Figure 4-1 and 4-2 illustrate the 96-hour release profiles of Latanoprost from balafilcon 
A and senofilcon A contact lenses loaded with different amount of drugs (Table 4-1). The 
release data for initial loading amount of 7.2 µg at the time point of 72 hours are not included 
due to sampling errors for both balafilcon A and senofilcon A contact lenses. The trend of 
release is presented by dash lines connecting data of between 48 and 96 hours’ time points for 
this condition.   
As shown in Figure 4-1, the lenses which were loaded with 7.2 and 29.0 µg of Latanoprost 
showed linear release kinetics (R2>0.98). No significant difference in the amount of drug 
released was observed (p=0.5480) at all time-points. On the other hand, the release rate for the 
contact lens loaded with the lowest amount of Latanoprost (4.3µg) decreased after 24 hours 
and reached an equilibrium showing a first-order decay rate (R² = 0.9492).  At 24 hours, all 
the amount of Latanoprost released for all three initial loading concentrations were above 
clinical therapeutic dose. The average release rates of balafilcon A with different initial loading 
concentrations are presented in Table 4-2.  The maximum average rate of release for balafilcon 
A was 36.5 ng/hour with the initial loading of ~7.2 µg Latanoprost whereas the minimum 
average release rate for balafilcon A was 7.3ng/hour with the initial loading amount of ~4.3 
µg. 
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Figure 4-1. Latanoprost release from balafilcon A contact lenses through live HCEC monolayer models. 
Lenses were soaked for 24 hours in drug solutions containing 4.3, 7.2 and 29.0 µg Latanoprost and then 
overlaid on the monolayer for 96 hours. Release experiments were conducted on three separate dates n = 3, 
Mean + SD except for drug solutions containing 7.2 µg Latanoprost n=2, Mean ± SD   
* Significantly different after 24 hr compared to 7.2 and 29.0 µg loading amount (p<0.0214) 
 
The release profile of Latanoprost from senofilcon A contact lenses loaded with different 
amount of drugs in a time course of 96 hours are presented in Figure 4-2.  The Latanoprost 
release profiles for senofilcon A have a similar trend compared to the release behavior of 
balafilcon A, regardless of the rate and the amount of drug released.  The release kinetics of 
senofilcon A with initial loading amount of 29.0 and 7.3 µg were zero-order (R2>0.98) with 
average rates of 44.2 and 36.4 ng/hour respectively (Table 4-2). However, the kinetics of 
Latanoprost release from senofilcon A with 4.3 µg loading amount was a first-order decay 
(R2=0.68) depleting the drug after 24 hours of release with the average rate of 14.6 ng/ml.  
Statistical analysis indicated that there was a significant effect of lens type on release kinetics 
(p<0.0001) and initial loading concentration significantly affected the rate of release from 
silicone hydrogel contact lenses. (p=0.0221) 
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Figure 4-2. Latanoprost release from senofilcon A contact lenses through live HCEC monolayer models. Lenses 
were soaked for 24 hours in drug solutions containing 4.3, 7.2 and 29.0 µg Latanoprost and then overlaid on the 
monolayer for 48 hours. Release experiments were conducted on three separate dates n = 3, Mean + SD except 
for drug solutions containing 7.2 µg Latanoprost n=2, Mean ± SD  
* Significantly different after 24 hours compared to 7.2 and 29.0 µg loading amount (p<0.0406) 
  
 
 
 
Table 4-2. Latanoprost average release rate from silicone hydrogel contact lenses in 96 hours 
Contact Lens Initial loading amount (µg) average release rate (ng/hour) 
balafilcon A 4.3 7.3±1.4* 
senofilcon A 14.6±5.3§* 
balafilcon A 7.2 36.5±19.6 
senofilcon A 44.2±2.6§ 
balafilcon A 29.0 19.1±1.8 
senofilcon A 34.6±6.7§ 
§ Significantly different compared to balafilcon A (p<0.0417) 
* Significantly different compared to 7.2 and 29.0 µg loading amount (p<0.0221) 
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4.4 Discussion 
This study was undertaken with the ultimate goal of designing a controlled release 
device using marketed contact lenses for extended release of Latanoprost for treatment of 
glaucoma. The short retention time on ocular surface and poor patient compliance due to the 
frequent dose requirement of topical eye drops are two of the main challenges in topical 
ophthalmic administration (Urtti, 2006). Using silicone hydrogel contact lenses has always 
been considered as an alternative solution to overcome these challenges (Kim et al., 2010, 
2008; Mohammadi et al., 2014; Peng and Chauhan, 2011; Peng et al., 2012).  
In this study, the impact of loading lower amount of drug on the rate and the amount of drug 
released in an extended delivery time (4 days) was assessed. The results showed that the 
therapeutic dose has been reached in 24 hours with all three initial loading amounts.  However, 
the release rates for the low loading amount (4.2 g) were not constant throughout the entire 
release period for both balafilcon A and senofilcon A reaching a plateau after 24 hours of 
release. Comparison between the uptake and the release amounts for this particular condition 
indicates that lenses have not been depleted, with only up to 32% being released. This 
saturation might be due to the equilibrium between the cellular active transport of Latanoprost 
and chemical interaction forces between hydrophobic Latanoprost molecules and the contact 
lens polymer matrix.  This could be a disadvantage for an extended drug delivery device. On 
the other hand, the release rates for both contact lenses loaded with 29 and 7.2 µg of 
Latanoprost were approximately constant throughout the entire experiment giving a zero order 
release. The maximum released amount of Latanoprost from both contact lenses in these 
conditions were in the range of ~3.2- 4.1 µg which are comparable to the released amount 
achieved by Mohammadi et al., 2014 although these amounts of Latanoprost are eluted in 96 
hours rather than 24 hours.  
Surprisingly, the release results showed a higher amount of drug eluted from senofilcon A 
loaded with 7.2 µg compared to senofilcon A loaded with 29.0 µg Latanoprost. While this 
indicates that soaking the senofilcon A lens in 7.2 µg of Latanoprost provides a drug delivery 
system just as effective as soaking the lens into 29 µg, the statistical difference observed may 
highlight some of the experimental variations that are observed with measuring concentration 
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of Latanoprost.  The high dilutions that are necessary to measure Latanoprost using the EIA 
are associated with high standard variations and may be at the origin of the currently observed 
statistical difference.  Similar large standard deviations were noted by Mohammadi et al., 
(2014). Further experiments will be required to confirm the difference observed in these 
experiments.   
The fact that, regardless of initial loading concentrations, senofilcon A released significantly 
higher amount of Latanoprost compared to balafilcon A is in agreement with previous results 
by Mohammadi et al. (2014). Our results with lower uploaded amounts indicates a release of 
more than 55% of uptaken drug into contact lenses, a significant improvement over the 4% 
obtained previously in our lab, suggesting that a simple, economical and cost effective drug 
delivery system can be obtained with silicone hydrogels and Latanoprost. 
In this study, we were able to obtain sustained release of Latanoprost in vitro for up to 4 days.  
There is currently limited data available on the effect of extended release of glaucoma drug on 
maintaining IOP at a healthy level as only the effects of drops have been studied in human.  
Previous work by Peng et al. (2012) demonstrated that using 4-day extended release of Timolol 
from drug/vitamin E loaded contact lenses on beagle dogs in vivo resulted in an IOP as low as 
the one associated with daily use of eye drops. The IOP was also significantly below the IOP 
baseline value for glaucoma eyes in the beagle dogs (Peng et al., 2012). In our experiments, 
the average rate of release for balafilcon A ranged from19.1 to 36.5 ng/hour for initial loading 
of 29.0 and 7.2 µg respectively while rates for senofilcon A were 34.6-44.2 ng/hour. Over a 4-
day period of contact lens wear, these rates of Latanoprost release can potentially satisfy the 
therapeutic daily dose of 150-300 ng/day and effectively lower IOP. Further investigations are 
necessary to confirm these release kinetics and their effectiveness in ex vivo and in vivo 
conditions or in a more complex in vitro model mimicking the dynamic environment of ocular 
surface.   
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Chapter 5  
Release System for Hydrophilic drug 
5.1 Introduction  
Timolol is a non-selective β-blocker which has been used widely for treatment of glaucoma 
and IOP hypertension for over 30 years (Neufeld et al., 1983). Timolol is a replacement for 
prostaglandin analogues or is prescribed in combination with other prostaglandin analogues 
like Latanoprost (Volotinen et al., 2011). Timolol reduces the IOP by controlling the formation 
of aqueous humor and is used conventionally in the form of eye drops (Neufeld et al., 1983). 
The Timolol molecule by itself is categorized as a lipophilic drug but it is commercially 
available in the hydrophilic form of 0.5% Timolol maleate gel forming solution in order to 
increase its duration of action on the ocular surface (Shedden et al., 2001).     
Ciprofloxacin HCl is a new generation of antibacterial agents which is very active against a 
broad range of Gram-positive and Gram-negative bacteria and has been widely prescribed in 
the form of eye drops as an antibiotic agent for ocular infections. Ciprofloxacin HCl is also a 
hydrophilic molecule (Campoli-Richards et al., 1988).  
Like any other topical ophthalmics, the main challenges for Ciprofloxacin HCl and Timolol 
maleate ocular delivery are their bioavailability and short residence time on ocular surface. 
Moreover due their hydrophilic nature, they would mainly permeate through the paracellular 
route because they cannot distribute into the cellular lipid bilayer membrane (Sakanaka et al., 
2006). Therefore extensive attempts have been made to implement a therapeutic contact lens 
system for extended release of these hydrophilic drugs using different techniques and 
strategies.  However the biggest obstacle in this effort, the burst release of the drug, seems to 
remain unconquerable. The  majority of these studies examined the release kinetics of drug 
loaded contact lenses in a fixed-volume in vitro model containing PBS or water, which is far 
from the ocular environment conditions (Holden et al., 2012; Hui et al., 2014, 2012; Kim et 
al., 2008; Nguyen et al., 2012; Peng et al., 2012).  
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The main objectives of this part of the project were to evaluate the release kinetics of 
hydrophilic drug eluting from silicone hydrogel contact lenses in vitro in the presence of 
corneal epithelial cells and compare them to their release kinetics in a fixed-volume in vitro 
model with no cells. The validity of the corneal in vitro model as the test platform for screening 
of the drug eluting biomaterials, against the hydrophilic drugs was also assessed. Previous 
work by Mohammadi et al., (2014) had only investigated the hydrophilic derivative of 
Latanoprost, Latanoprost free-acid.  Alternative low cost and fast analytical technique 
(spectrophotometry) allowing the real-time measurements of the drug concentration were other 
factors leading us to switch to hydrophilic drugs other than Latanoprost free-acid, which 
requires an expensive and laborious EIA analytical method. 
 To address these objectives, we assessed and statistically compared the uptake and the release 
kinetics of balafilcon A and senofilcon A silicone hydrogel contact lenses uploaded with 
Ciprofloxacin HCl and Timolol maleate in three in vitro models: no cell, live cell and fixed 
cell.   
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5.2 Materials and Methods 
5.2.1 Preparation of Drug Solution 
The drug solutions were prepared by dissolving of Ciprofloxacin HCl (Sigma-Aldrich) 
and Timolol Maleate (Sigma-Aldrich) in cell culture water (Lonza, Walkersville, MD). The 
expected concentration of Ciprofloxacin HCl stock drug solution was 3000 µg/ml and the 
expected concentration of Timolol Maleate was 1000 µg/ml based on the drug amount claimed 
on the labels by the manufacturers. The actual concentrations were measured by 
spectrophotometry and are presented in Table 5.1 and Table 5.2. Stock solutions were stored 
at -20 °C. 
5.2.2 Calibration curve  
In order to calculate the drug concentrations based on the light absorbance using a UV-
Visible spectrophometry technique, a standard curve by serial dilutions of drugs at 
concentrations of 1, 2, 3, 5, 7, 10, 12, 15 and 20 µg/ml was developed. Absorbance of 
Ciprofloxacin HCl and Timolol Maleate were measured at the wavelengths of 274 and 295 nm 
respectively.   The calibration curves for Ciprofloxacin HCl and Timolol Maleate are presented 
in Figure 5-1 and 2. 
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Figure 5-1. Ciprofloxacin HCl standard curve. Drug absorbance was read at λ=274 nm. 
 
 
 
Figure 5-2. Timolol Maleate standard curve. Drug absorbance was read at λ=295 nm. 
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5.2.3 Preparation of Contact Lenses 
Two commercially available silicone hydrogel contact lenses, balafilcon A and 
senofilcon A were used in this study. The chemical properties of these lenses were presented 
in Table 3-1. Lenses were first incubated for 24 hours in PBS to remove any remnants of their 
packaging solution. The lenses were then incubated in 1.5ml of the drug solution for 24 hours. 
5.2.4 Hydrophilic Drugs Uptake and Release 
After a 24 hour incubation in PBS, contact lenses were soaked in 1.5ml of drug solution 
for 24 hours. The lenses were put on three release models (No cell, Fixed and Live monolayer). 
The volume of liquid in the cell insert was 0.5ml and 1.0ml in the bottom well. The release 
was studied for up to 48 hours. Aliquots of 100 µl were taken from the bottom of the in vitro 
models and replaced by fresh culture medium. Samples were taken at 1, 4, 8, 12, 24 and 48 
hours. Collected samples were analyzed via a UV-Vis spectrophometry (SPECTRA max 
PLUS 384 Made in USA) at wavelengths of 274 nm and 295 nm for Ciprofloxacin HCl and 
Timolol Maleate respectively. To determine the uptake amount by the contact lenses, samples 
were also collected from the soaking drug solution as well as the remaining drug solutions after 
soaking the lenses. Each set of experiment were repeated 3 times independently. Drug 
concentrations were calculated based on the equation explained previously in Chapter 3.  
5.2.5 Data Analysis 
Results presented here are the mean±standard deviation of three independent 
experiments. Statistical analysis of data was performed by two-way analysis of variance 
(ANOVA) using Minitab Express™ Software. A p value of less than 0.05 was required for 
statistical significance.   
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5.3 Results  
5.3.1 Ciprofloxacin HCl Uptake and Release 
The uptake and release amount of Ciprofloxacin HCl from balafilcon A and senofilcon A 
with initial loading concentration are presented in Table 5-1. The total Ciprofloxacin HCl 
uptake by balafilcon A was 4672.8±60.4µg after 24 hours which was 14.1±6.1% of the total 
available drug to the contact lens. The total amount of the drug uptaken by senofilcon A was 
4726.2±105.6 µg or 43.6±1.4% of the available drug in the 1.5 ml doping solution. The 
Ciprofloxacin uptake by senofilcon A was significantly higher than that of balafilcon A 
(p<0.0001). The maximum amounts of Ciprofloxacin HCl released from balafilcon A after 48 
hours were 145.2±20.1, 143.9±16.1 and 186.2±31.0 µg in the live monolayer, fixed monolayer 
and no-cell models respectively, whereas the maximum released drug from senofilcon A were 
45.1±2.2, 42.2±0.3 and 58.3±2. 6 µg for live, fixed and no-cell models respectively. While 
senofilcon A uptake was higher than balafilcon A, the amounts of Ciprofloxacin HCl released 
from senofilcon A in all three models were significantly lower than from balafilcon A 
(p<0.0001). While there was no significant difference in Ciprofloxacin HCl released between 
the live and fixed model (p= 0.7867), the released amount of Ciprofloxacin HCl was 
significantly higher in the no-cell model compared to live and fixed models regardless of 
contact lens material (p= 0.0170).  
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Table 5-1. Ciprofloxacin HCl uptake into balafilcon A and senofilcon A contact lenses and total amount of drug released after 48 hours through the live HCEC 
monolayer in vitro model. Lenses were soaked for 24 hours in drug solutions (3000 µg/ml) and then drug uptake into the lens were measured. Uptake and release 
experiments were conducted in three separate dates n = 3, Mean + SD 
Theoretical concentration1 
(µg Ciprofloxacin/ml) 
3000 
Actual loading concentration2 
(µg Ciprofloxacin/ml) 
2942.0±70.4 
In vitro Model  Live Monolayer Fixed Monolayer No-cell* 
 Uptake§ Release§ Release§ Release§ 
 (%) (µg) (%) (µg) (%) (µg) (%) (µg) 
balafilcon A 14.1±6.1 4672.8±60.4 3.1±0.4 145.2±20.1 30.8±0.3 143.9±16.1 39.9±0.7 186.2±31.0 
senofilcon A§ 43.6±1.4 4726.2±105.6 0.9±0.1 45.1±2.2 0.9±0.0 42.2±0.3 1.2±0.1 58.3±2. 6 
1 Expected (nominal) concentration based on the manufacturer’s label. 
2 Concentration of the solution measured by Spectrophotometry 
* Significantly different compared to fixed and live models (p<0.0170) 
§ Significantly different compared to balafilcon A (p<0.0001) 
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The release profile of Ciprofloxacin HCl from balafilcon A through no-cell, live and fixed 
monolayer in vitro models are presented in Figure 5-3. As can be seen on Figure 5-3, the release 
profiles of Ciprofloxacin in all three models were not linear, indicating that the rate of release 
from contact lens is not constant regardless of the in vitro model. The amount of drug release 
in the no-cell model was significantly higher and a faster equilibrium can be observed in this 
model. In the no-cell model, about ~70% of the maximum released amount of Ciprofloxacin 
HCl was eluted in the media in the first 8 hours of the experiments while only ~45% and ~53% 
of the maximum released amounts were depleted from balafilcon A lenses in this period  of 
time in the live and fixed models respectively.  
The release profile of Ciprofloxacin HCl from senofilcon A through no-cell, live and fixed 
monolayer in vitro models are presented in Figure 5-4. Similarly to balafilcon A, the release 
profiles of Ciprofloxacin HCl from senofilcon A did not present a zero-order release regardless 
of the in vitro models used, although the amount of drug release in the no-cell model was 
significantly higher compared to the live and fixed models. In the no-cell model about ~66% 
of the maximum released amount of the drug was eluted in the first 12 hours of the experiments 
while only ~47% and ~57% of the maximum released amounts were released from senofilcon 
A in the live and fixed models respectively after 12 hours.  
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Figure 5-3 Ciprofloxacin HCl release from balafilcon A contact lenses through live and fixed HCEC monolayer 
and No-cell models. Cells were fixed in 2% paraformaldehyde. Lenses were soaked for 24 hours in drug 
solution (3000 µg/ml) and then overlaid on the monolayer for 48 hours. Release experiments were conducted 
in three separate dates n = 3, Mean + SD. 
* Significantly different than fixed and live models (p<0.0094) 
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Figure 5-4. Ciprofloxacin HCl release from senofilcon A contact lenses through live and fixed HCEC 
monolayer and No-cell models. Cells were fixed in 2% paraformaldehyde. Lenses were soaked for 24 hours in 
drug solution (3000 µg/ml) and then overlaid on the monolayer for 48 hours. Release experiments were 
conducted in three separate dates n = 3, Mean + SD. 
* Significantly different than fixed and live models (p<0.0015) 
 
5.3.2 Timolol Maleate Uptake and Release 
The uptake and release amount of Timolol maleate from balafilcon A and senofilcon 
A lenses with their initial loading concentrations are presented in Table 5-2. The total Timolol 
available to contact lenses was 16677±18.8 µg and the total uptake by balafilcon A after 24 
hours was 1591.1±72.2µg or 10.9±3.5% of the total available drug. The total amount of the 
drug uptaken by senofilcon A was 1602.4±170.7 µg or 10.6±5.5% of available drug to the lens. 
There was no significant difference in Timolol uptakes between senofilcon A and balafilcon 
A (p=0.6108).  The total amounts of Timolol released from balafilcon A after 48 hours were 
56.9±17.7, 37.1±6.7 and 35.2±15.5µg in the live, fixed and no-cell models respectively, 
whereas the maximum released amount of the drug from senofilcon A were 45.3±19.2, 
28.5±9.4 and 29.3±15.6µg for live, fixed and no-cell models respectively. There was a 
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significant difference between contact lens material in the amount of released Timolol 
regardless of the in vitro model used (p<0.0001).  No significant difference in the released 
amount of the drug after 48 hours was observed between the no cell, live and fixed models, 
regardless of contact lens material (p= 0.2391). 
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 Table 5-2 Timolol Maleate uptake into balafilcon A and senofilcon A contact lenses and total amount of drug released after 48 hours through the live HCEC 
monolayer in vitro model. Lenses were soaked for 24 hours in drug solutions (1000 µg/ml) and then drug uptake into the lens were measured. Uptake experiments 
were conducted in three separate dates n = 3, Mean + SD 
Theoretical concentration1 
(µg Timolol/ml) 
 
1000 
Actual loading concentration2 
(µg Timolol/ml) 
 
1118.2±12. 6 
In Vitro Model  Live Monolayer Fixed Monolayer No-cell 
 Uptake Release Release Release 
 (%) (µg) (%) (µg) 
 
(%) 
 
(µg) 
 
(%) 
 
(µg) 
balafilcon A 10.9±3.5 1591.1±72.2 3.6±1.1 56.9±17.7 2.3±0.4 37.1±6.7 22.1±1.0 35.2±15.5 
senofilcon A§ 10.6±5.5 1602.4±170.7 2.8±1.2 45.3±19.2 1.8±0.6 28.5±9.4 1.8±1.0 29.3±15.6 
1 Expected (nominal) concentration based on the manufacturer’s label.  
2 Concentration of the solution measured by Spectrophotometry 
§ Release significantly different compared to balafilcon A (p<0.0001)
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The release profile of Timolol maleate from balafilcon A through no-cell, live and fixed 
monolayer in vitro models are presented in Figure 5-5. As can be observed, the release rates of 
Timolol in all in vitro models are not constant. The rate of release diminishes after 12 hours 
approaching the equilibrium regardless of lens type and in vitro models used; this indicates a 
first-order release rate. However, unlike Ciprofloxacin HCl release results, there was no 
significant difference in the amount of Timolol released in the no-cell model compared to the 
fixed and live models, but a faster rate to reach the saturation can be observed in this model 
compared to fixed and live models. In the no-cell model about ~83% of the maximum released 
amount of Timolol was eluted in the beginning of the experiments (4 hours) while only ~47% 
and ~46% of the maximum released amounts were depleted from balafilcon A lenses in this 
period of time in the live and fixed models respectively. The release profile of Timolol from 
senofilcon A through no-cell, live and fixed monolayer in vitro models are presented in Figure 
5-6. Similar to balafilcon A, the release profiles of Timolol from senofilcon A do not present 
a constant rate of release regardless of the in vitro models tested. However, the amount of drug 
released in the no-cell model was significantly higher for this lens with an initial burst of ~62% 
of the total released drug while, after 4 hours, ~36% and ~35% of the maximum released 
amounts were released from balafilcon A in the live and fixed models respectively.  
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Figure 5-5. Timolol Maleate release from balafilcon A contact lenses through live and fixed HCEC 
monolayer and No-cell models. Cells were fixed in 2% paraformaldehyde. Lenses were soaked for 24 hours 
in drug solution (1000 µg/ml) and then overlaid on the monolayer for 48 hours. Release experiments were 
conducted in three separate dates n = 3, Mean + SD. 
* Significantly different than fixed and live models (p<0.0164) 
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Figure 5-6. Timolol Maleate release from senofilcon A contact lenses through live and fixed HCEC 
monolayer and No-cell models. Cells were fixed in 2% Paraformaldehyde. Lenses were soaked for 24 hours 
in drug solution (1000 µg/ml) and then overlaid on the monolayer for 48 hours. Release experiments were 
conducted in three separate dates n = 3, Mean + SD. 
* Significantly different than fixed and live models (p<0.0196) 
 
 
 
5.4 Discussion 
In this part of the project, we assessed in vitro the release kinetics of drug eluting 
silicone hydrogel contact lenses loaded with hydrophilic Ciprofloxacin HCl and Timolol 
Maleate in the presence of corneal epithelial cells and compared them to their release kinetics 
in a fixed-volume in vitro model with no-cells. The main problem reported extensively by 
studies on drug-soaked commercially marketed contact lenses is the release time, which is 
limited to minute to hours (Campoli-Richards et al. 1988; Karlgard et al. 2003; Hui et al. 2008; 
Nguyen et al. 2012). Several strategies have been explored to improve the release kinetics of 
commercially available contact lenses such as loading Vitamin E as a diffusional barrier to 
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slow down the release and extend the drug delivery (Hsu et al., 2013; Hui et al., 2014; Peng et 
al., 2012).   
Hui et al. have investigated the uptake and release of Ciprofloxacin HCl by commercially 
available conventional and silicone hydrogel contact lenses.  Three different contact lenses 
were soaked in  6000 µg of the drug (2 ml of 0.3% Ciprofloxacin solution in PBS). The contact 
lenses released an average amount of 133 µg/lens but the drug release reached a plateaue within 
10 minutes. Despite attemps to modify Ciprofloxacin release kinetics using molecular 
imprinting techniques with a model silicone hydrogel contact lens (Hui et al., 2014), fixed-
volume in vitro results in borate buffered saline (BBS) showed a maximum release of 361±5μg 
of  Ciprofloxacin over a 6 day period where ~87% of the drug was released in the first day by 
an initial burst.  While our results tend to agree with Hui el as for the fact that a plateau is 
reached early on, our slightly longer time of release before saturation may be due the difference 
in material chemistry (balafilcon A and senofilcon A were not tested in that study) as well as 
the difference in release medium (PBS versus KSFM).  Mohammadi et al have previously 
reported a small difference in release between PBS and KSFM.   
Our no-cell, live and fixed model results are comparable with previously published in vitro 
release results for Timolol (Saettone et al. 1996; Kim et al. 2008; Peng et al. 2012) whereby it 
was observed that the release rate of hyrophilic Timolol from silicone hydrogels follows a first 
order kinetics.The difference in results between rate and amount of released drug are due to 
the difference in release media, contact lens material and in vitro experimental models. 
Comparison of cirpfloxacin HCl and Timolol maleate release profile with Latanoprost 
indicates that presence of live cells in the model do not change the order of release rate to a 
constant zero-order decay. Since hydrophilic drugs permeate via paracellular routes by passive 
difussion rather than active cell transport, presence of cells in the release model act as a 
diffussion barrier and prolongs the release kinetics of hydrophilic drugs (Sakanaka et al., 
2006). The similarities in results between the live and fixed cell models for Timolol and 
Ciprofloxacin from both contact lens materials further supports this hypothesis.  
Our in vitro results agree with works of others (Hui et al., 2014, 2012, 2008; Nguyen et al., 
2012) that the release kinetics of hydrophilic drugs from silicone hydrogels follow the first-
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order decay rate.  However, our in vitro release experiments in the presence of corneal 
epithelial cells, which  act as an active barrier also highlight that the release of hydrophilic 
drugs from commercial contact lenses is prolonged when tested with realistic diffusion and 
permeation conditions.  While the difference may be small and has minimal impact on the poor 
outcome of soaking contact lenses in hydrophilic drugs, our data further highlight the 
difference that the presence of cells has when assessing drug release in vitro.    
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Chapter 6 
Conclusions 
 
The cornea is the main barrier against the permeation of ocular drugs to the anterior 
chamber. Hydrophobic and hydrophilic drugs permeate through different transcorneal routes. 
In feasibility assessment of drug delivery contact lenses, the role of these barriers and the 
biological interaction of corneal cells with the drug/lens complex must be taken into account. 
In this thesis, the presence of the prostaglandin transporter OATP 2A1 in immortalized human 
corneal epithelial cell line has been verified. The role of drug transporters in transcorneal 
permeation becomes important when hydrophobic drugs interact with the cornea. The active 
transcellular transport plays an important role in transcorneal permeation of hydrophobic 
molecules. Fixing cells almost entirely abolish transcorneal permeation of the hydrophobic 
Latanoprost; ~90% decrease in the permeation of the drug was observed compared to the live 
cell model. Inhibition of the prostaglandin transporter OATP 2A1 significantly decreased the 
rate and the amount of Latanoprost released from both contact lens materials tested. Only 50% 
of Latanoprost transport was inhibited suggesting that the active transcellular transport of 
Latanoprost may not be mediated only by OATP 2A1. Other transporters might be involved in 
transport of Latanoprost as well. From our in vitro experiments, it appears that a combination 
of mechanisms are involved which are driven mainly by transcellular molecular mediated 
active transport and partially by passive diffusion-solution through lipid bilayers of cell 
membranes. These mechanisms govern the total permeation of hydrophobic drugs across the 
corneal epithelium.  
 
Proper dosing and a sustainable zero-order release rate are the ultimate goals in designing 
therapeutic contact lenses. Silicone hydrogels showed a zero-order release profile for 
Latanoprost when assessed in vitro in the presence of corneal epithelial cells. Initial loading 
concentration of the drug had a significant effect on the rate of release.  
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The uptake of hydrophilic drugs by silicone hydrogels were significantly lower than the uptake 
of hydrophobic Latanoprost, and the released amount of hydrophilic drugs were significantly 
higher than Latanoprost. Hydrophilic drugs have lower affinity to silicone hydrogels than 
hydrophobic molecules. Our results further confirm that chemical interaction between drug 
molecules and contact lens polymer must be taken into account in the design of the controlled 
release system. As well, the testing conditions and presence of biological barriers provided by 
cells can produce a more realistic test platform for studying the release kinetics for the ocular 
environment. All in all, this thesis confirms the importance of proper selection of in vitro test 
models for the assessment of ocular drug delivery system.  
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Chapter 7 
Recommendations for Future Works 
 
This research contributes a small building block to the massive construction of ocular drug 
delivery science but leaves also us with many unanswered questions. The following are few 
recommendations for future research. 
To further characterize the corneal in vitro model and assess the corneal permeation, it is 
recommended to test more combination of hydrophobic ophthalmics and silicone hydrogel 
lenses, this may give more solid ground to stand on and make more inferences on mechanism 
of corneal drug transport. It is also recommended to characterize the human corneal epithelial 
cell line for drug metabolism enzymes and esterase activity of the enzymes on prodrugs.  
To obtain more valid in vitro release data, it is recommended to measure the Latanoprost and 
other drugs release rates in an in vitro model with a dynamic condition mimicking the ocular 
environment. For instance in order to have an in vitro model which has a better prediction of 
in vivo results, it is recommended to study the release rate of the drugs from different contact 
lens materials on a stratified curved corneal 3D construct and test them under the effect of tear 
replenishment with the newly developed microfluidics tear replenishment system (TRS) at the 
MIBS lab.  
Performing ex vivo experiments with excised animal cornea may help to assess the corneal 
penetration rate as well as provide comparison points to evaluate the validity of in vitro results. 
Ex vivo experiment can also be performed in a dynamic environment. 
Mathematical modeling of contact lens release mechanism in the corneal in vitro model may 
provide a predictive tool for the design of therapeutic contact lens as well as for prediction of 
transcorneal drug diffusion.  
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Appendix A  Complementary Experiments 
In order to understand the effect of membrane material used in cell culture inserts on the release 
profile of Latanoprost, a set of experiments was designed in absence of contact lenses. 0.5 ml 
of 161µg/ml Latanoprost solution in PBS was added on top of a monolayer grown on PET and 
cellulose inserts and 1ml of KSFM to the bottom. 100µl of samples were taken every 30 
minutes up to 4 hours and then after 12 and 24 hours. Samples were analyzed using EIA kit.  
  
 
Figure 7-1. Latanoprost release experiment, through cellulose membrane inserts versus Polyethylene 
terephthalate (PET) membrane, monolayer of (HCECs) with no contact lens, and drug solution on top with 
initial concentration of 161 µg/ml. All membranes were collagen-coated prior to cell culture and release 
experiments. . n=2, Mean ±SD  
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Figure 7-2 MTT viability test on live, transporter inhibited and fixed HCEC monolayer models. Cells were 
incubated with 100µM Diclofenac sodium for 24 hours to inhibit the transporters. Cell were fixed in 2% 
paraformaldehyde solution in PBS for 24 hours. n=3, Mean ±SD 
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Figure 7-3 MTT viability test performed on live and fixed HCEC monolayer models after Ciprofloxacin HCl 
release experiments. Ciprofloxacin HCl concentration was 3 mg/ml in the No-Lens model. Cells were fixed 
in 2% paraformaldehyde solution in PBS for 24 hours. n=3, Mean ±SD 
 
 
Figure 7-4 MTT viability test performed on live and fixed HCEC monolayer models after Timolol maleate 
release experiments. Timolol Maleate concentration was 1 mg/ml in the No-Lens model. Cells were fixed in 
2% paraformaldehyde solution in PBS for 24 hours. n=3, Mean ±SD 
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